{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 106,
   "metadata": {},
   "outputs": [],
   "source": [
    "from ollama import Client\n",
    "\n",
    "client = Client(host='http://192.168.0.107:11434')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 69,
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "import json\n",
    "\n",
    "def read_local_json(name): \n",
    "    \n",
    "    with open(f'./{name}.json') as f:\n",
    "        data = json.load(f)\n",
    "\n",
    "    return data\n",
    "\n",
    "output_template = read_local_json('output_template')\n",
    "\n",
    "criteria = output_template['Output']['evaluate_trials'][0]['criteria']\n",
    "patient_profile = output_template['Output']['patient_profile']\n",
    "\n",
    "VOTE_CNT = 3"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 103,
   "metadata": {},
   "outputs": [],
   "source": [
    "def construct_msg(patient_des, criteria, criteria_type=\"\"):\n",
    "    messages = [\n",
    "    {\n",
    "            \"role\": \"system\",\n",
    "            \"content\": \"You are a helpful assistant that answers in JSON.\",\n",
    "    },\n",
    "    {\n",
    "      \"role\": \"system\",\n",
    "      \"content\": f'''\n",
    "      You are responsible for analyzing patient profile and clinical trials criteria. Detailed factors and conditions in the criteria should be considered, do not make assumption when patient information is not enough. \n",
    "      First, You will be provided with the a clinical trial criterion. \n",
    "      Next, You will be provided with the patient profile. \n",
    "      ''',\n",
    "        },\n",
    "    {\n",
    "      \"role\": \"user\",\n",
    "      \"content\": f'''\n",
    "        Here is the clinical trial {criteria_type} criterion:\n",
    "        ${criteria}\n",
    "        '''\n",
    "    },\n",
    "    {\n",
    "      \"role\": \"user\",\n",
    "      \"content\": f'''\n",
    "        Here is the patient profile:\n",
    "        ${patient_des}\n",
    "        '''\n",
    "    },\n",
    "    {\n",
    "      \"role\": \"system\",\n",
    "      \"content\": f'''\n",
    "      Now, Try to assess if the patient profile matches the criterion.\n",
    "      ''',\n",
    "    }\n",
    "    ]\n",
    "\n",
    "    inclusion_msg = {\n",
    "      \"role\": \"system\",\n",
    "      \"content\": f'''\n",
    "      Finally, parse and return the result in JSON format:\n",
    "        - match_result: one of the three possible values below indicating criterion matching result based on the patient profile\n",
    "            * positive (The patient meets the requirement as stated in the inclusion criterion. The patient's profile aligns with the stated conditions or factors. This increases the chances of the patient being admitted into the clinical trial.)\n",
    "            * neutral (The patient's profile neither clearly meets nor fails to meet the inclusion criterion. It's possible that some information is missing, not specific enough, or there may be some uncertainty about how well the patient aligns with the criterion. In this case, further information or tests might be required.)\n",
    "            * negative (The patient does not meet the requirement as stated in the inclusion criterion. The patient's profile does not align with the conditions or factors stated and hence the patient is not suitable for the clinical trial.)\n",
    "        - comment: comment on the evidence supporting one of the three values given for the criterion matching result based on the patient profile\n",
    "      ''',\n",
    "    }\n",
    "\n",
    "    exclusion_msg = {\n",
    "      \"role\": \"system\",\n",
    "      \"content\": f'''\n",
    "      Finally, parse and return the result in JSON format:\n",
    "        - match_result: one of the three possible values below indicating criterion matching result based on the patient profile\n",
    "            * positive (The patient meets the requirement as stated in the exclusion criterion, meaning the patient has certain conditions or factors that disqualify them from the clinical trial.)\n",
    "            * neutral (The patient's profile neither clearly meets nor fails to meet the exclusion criterion. It's possible that some information is missing, not specific enough, or there may be some uncertainty about how well the patient aligns with the criterion. In this case, further information or tests might be required.)\n",
    "            * negative (The patient does not meet any of the conditions or factors stated in the exclusion criterion. This means none of the disqualifying factors are present in the patient's profile, making them potentially suitable for the clinical trial.)\n",
    "        - comment: comment on the evidence supporting one of the three values given for the criterion matching result based on the patient profile\n",
    "      ''',\n",
    "    }\n",
    "\n",
    "    non_spec_msg = {\n",
    "      \"role\": \"user\",\n",
    "      \"content\": f'''\n",
    "      Format the assessment result in the following JSON format:\n",
    "        - match_result: one of the three possible values below indicating criterion matching result based on the patient profile\n",
    "            * positive (meaning Patient profile contains the piece of information mentioned in the criterion and it meets this criterion)\n",
    "            * neutral (meaning more information is needed from the Patient profile to determine if this patient meet the criterion)\n",
    "            * negative (meaning Patient profile contains the piece of information mentioned in the criteria but it does not meet the criteria)\n",
    "        - comment: comment on the evidence supporting one of the three values given for the criterion matching result based on the patient profile\n",
    "      ''',\n",
    "        }\n",
    "\n",
    "    if criteria_type == \"exclusion\":\n",
    "       messages.append(exclusion_msg)\n",
    "    elif criteria_type == \"inclusion\":\n",
    "       messages.append(inclusion_msg)\n",
    "    else:\n",
    "       messages.append(non_spec_msg)\n",
    "\n",
    "    return messages\n",
    "\n",
    "def lambda_handler(criterion, patient_profile):\n",
    "  \n",
    "  messages = construct_msg(patient_profile, criterion['criterion'], criterion['type'])\n",
    "\n",
    "  result_llama = None\n",
    "  while result_llama is None:\n",
    "      try:\n",
    "        response = client.chat(model='llama3:8b', messages=messages)\n",
    "        result_llama = json.loads(response['message']['content'])\n",
    "      except Exception as e:\n",
    "          print(response['message']['content'])\n",
    "          pass\n",
    "\n",
    "  return {\n",
    "          \"id\": criterion['id'],\n",
    "          \"type\": criterion['type'],\n",
    "          \"criterion\": criterion['criterion'],\n",
    "          \"match_result\": result_llama['match_result'],\n",
    "          \"comment\": result_llama['comment']\n",
    "  }\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 104,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "###### Total: 34\n",
      "##### VOTE Round 0#####\n",
      "0;1;2;{\n",
      "\"match_result\": \"negative\",\n",
      "\"comment\": \"The patient does not have symptomatic brain or leptomeningeal metastases, and their CNS symptoms are stable. Additionally, they do not require increasing doses of steroids and/or anti-seizure medications to manage CNS symptoms within two weeks prior to starting dacomitinib.\"\n",
      "3;4;5;6;7;8;9;10;11;12;13;14;15;16;17;18;{\n",
      "\"match_result\": \"positive\",\n",
      "\"comment\": \"The patient's ECOG score is 0, which meets the inclusion criterion. Additionally, the patient has EGFR activating mutation (exon 19 deletion), which aligns with the criterion. All other factors and biomarkers also match, making it likely for the patient to meet the trial's inclusion criteria.\"\n",
      "19;20;21;22;23;24;25;{\n",
      "\"match_result\": \"positive\",\n",
      "\"comment\": \"The patient's ANC (16,000 cells/mm) meets the criterion of having an ANC ≥15,000 cells/mm3, which increases the chances of the patient being admitted into the clinical trial.\"\n",
      "{\n",
      "\"match_result\": \"positive\",\n",
      "\"comment\": \"The patient's ANC (Absolute neutrophil count) is 16,000 cells/mm3, which meets the requirement ≥15,000 cells/mm3. Additionally, there are no other factors mentioned in the criterion that would exclude the patient from the clinical trial.\"\n",
      "{\n",
      "\"match_result\": \"positive\",\n",
      "\"comment\": \"The patient's ANC (Absolute neutrophil count) is 16,000 cells/mm3, which meets the requirement ≥15,000 cells/mm3. Additionally, there are no other factors mentioned in the criterion that would exclude the patient from the clinical trial.\"\n",
      "26;{\n",
      "\"match_result\": \"positive\",\n",
      "\"comment\": \"The patient's platelet count (110,000 cells/mm) is greater than or equal to 100,000 cells/mm, which meets the inclusion criterion.\"\n",
      "27;28;29;30;31;32;33;\n",
      "##### VOTE Round 0#####\n",
      "\n",
      "##### VOTE Round 1#####\n",
      "0;1;2;3;4;5;6;7;8;9;{\n",
      "\"match_result\": \"negative\",\n",
      "\"comment\": \"The patient does not have clinically important abnormalities in cardiac rhythm, conduction or morphology of resting ECG. There are no issues with heart block or other cardiac conditions that would disqualify them from the clinical trial.\"\n",
      "10;11;12;13;14;15;16;{\n",
      "\"match_result\": \"positive\",\n",
      "\"comment\": \"The patient's EGFR activating mutation (exon 19 deletion) in tumor specimen matches the inclusion criterion, which requires an EGFR activating mutation (exon 19 deletion or L858R mutation in exon 21). The patient also meets other conditions such as having no history of small cell or carcinoid lung cancer and no systemic therapy received for advanced NSCLC.\"\n",
      "17;18;19;{\n",
      "\"match_result\": \"negative\",\n",
      "\"comment\": \"The patient has a history of EGFR activating mutation (exon 19 deletion), which is not permitted according to the inclusion criterion. Prior treatment with an EGFR-TKI or other TKIs is not allowed, and this patient meets that condition.\"\n",
      "20;21;22;23;24;25;26;27;28;29;30;31;32;33;\n",
      "##### VOTE Round 1#####\n",
      "\n",
      "##### VOTE Round 2#####\n",
      "0;1;2;3;4;5;6;{\n",
      "\"match_result\": \"negative\",\n",
      "\"comment\": \"The patient has Non-Small Cell Lung Cancer, Adenocarcinoma, with a specific gene mutation (EGFR activating mutation) and no history of small cell or carcinoid lung cancer. They also meet the other specified criteria such as having at least one unirradiated target lesion according to RECIST v1.1. The patient's biomarkers are within normal limits except for platelets, which are slightly above normal. Since none of these conditions or factors match the exclusion criterion ($Current enrollment in another therapeutic clinical study;), this patient does not meet any of the disqualifying criteria and is potentially suitable for the clinical trial.\"\n",
      "7;8;9;{\n",
      "\"match_result\": \"negative\",\n",
      "\"comment\": \"The patient does not have any clinically important abnormalities in cardiac rhythm, conduction or morphology of resting ECG that would exclude them from the clinical trial. Additionally, there are no other exclusion criteria mentioned that would apply to this patient's profile.\"\n",
      "10;11;12;13;14;15;16;17;18;19;20;21;22;23;24;25;26;27;{\n",
      "\"match_result\": \"positive\",\n",
      "\"comment\": \"The patient's hemoglobin level (11.0 g/dL) meets the inclusion criterion requirement (Hemoglobin ≥10.0 g/dL), indicating that this patient can be considered for the clinical trial.\"\n",
      "{\n",
      "\"match_result\": \"positive\",\n",
      "\"comment\": \"The patient's hemoglobin level (11.0 g/dL) meets the inclusion criterion requirement (Hemoglobin ≥10.0 g/dL), indicating that the patient is suitable for the clinical trial.\"\n",
      "28;29;30;31;32;33;\n",
      "##### VOTE Round 2#####\n",
      "\n"
     ]
    }
   ],
   "source": [
    "final_output = []\n",
    "\n",
    "print(f\"###### Total: {len(criteria)}\")\n",
    "for vote_round in range(VOTE_CNT):\n",
    "    print(f\"##### VOTE Round {vote_round}#####\")\n",
    "\n",
    "    criteria_llama = []     \n",
    "\n",
    "    \n",
    "    for id, criterion in enumerate(criteria):\n",
    "        \n",
    "        print(id, end=';')\n",
    "\n",
    "        if \"match_result\" in criterion.keys():\n",
    "\n",
    "            result_criterion = lambda_handler(criterion, patient_profile)\n",
    "            criteria_llama.append(result_criterion)\n",
    "        else:\n",
    "            criteria_llama.append(criterion)\n",
    "\n",
    "        \n",
    "\n",
    "    output_template_new = read_local_json('output_template')\n",
    "    output_template_new['Output']['evaluate_trials'][0]['criteria'] = criteria_llama\n",
    "\n",
    "    final_output.append(output_template_new)\n",
    "    print(f\"\\n##### VOTE Round {vote_round}#####\\n\")\n",
    "    \n",
    "final_output = json.dumps(final_output)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 105,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[{\"ExecutionArn\": \"arn:aws:states:ap-east-1:201053736981:execution:clinmatch_match_patient_trial_evaluation_LLM_sub_process_no_vote:f6ead184-b7e3-4fa5-aee1-ae21f26f2301\", \"Input\": {\"patient_profile\": \"Patient with Non-Small Cell Lung Cancer, Adenocarcinoma. Disease occurred in lung. Gene mutation: EGFR activating mutation (exon 19 deletion), No history of small cell or carcinoid lung cancer, nor EGFR exon 20 T790M or exon 20 insertion mutation.. ECOG score is 0. Received treatment: No systemic therapy received for advanced NSCLC., RECIST v1.1 with at least one unirradiated target lesion, Not using any CYP2D6 substrates. Biomarkers are Platelets: 110,000 cells/mm, Creatinine: 35 mL/min, ALT (SGPT): Within normal limits, AST (SGOT): Within normal limits, Bilirubin, Total: 1.2 x ULN, ECOG: 0, ANC: 1600 cells/mm, Hemoglobin: 11.0 g/dL, Bilirubin: 1.2 x ULN. Other health status: Smoking status unknown.\", \"ranked_sql_trials\": [\"NCT04027647\", \"NCT04989322\", \"NCT05261399\", \"NCT05526755\", \"NCT05133544\", \"NCT05170204\", \"NCT04782557\", \"NCT05425940\", \"NCT05099172\", \"NCT05048797\"], \"number_evaluate\": 5}, \"Output\": {\"patient_profile\": \"Patient with Non-Small Cell Lung Cancer, Adenocarcinoma. Disease occurred in lung. Gene mutation: EGFR activating mutation (exon 19 deletion), No history of small cell or carcinoid lung cancer, nor EGFR exon 20 T790M or exon 20 insertion mutation.. ECOG score is 0. Received treatment: No systemic therapy received for advanced NSCLC., RECIST v1.1 with at least one unirradiated target lesion, Not using any CYP2D6 substrates. Biomarkers are Platelets: 110,000 cells/mm, Creatinine: 35 mL/min, ALT (SGPT): Within normal limits, AST (SGOT): Within normal limits, Bilirubin, Total: 1.2 x ULN, ECOG: 0, ANC: 1600 cells/mm, Hemoglobin: 11.0 g/dL, Bilirubin: 1.2 x ULN. Other health status: Smoking status unknown.\", \"evaluate_trials\": [{\"trial_id\": \"NCT04027647\", \"gpt_result_score\": 13, \"criteria\": [{\"id\": 0, \"type\": \"exclusion\", \"criterion\": \"Any evidence of mixed histo- and/or cytology that includes elements of small cell or carcinoid lung cancer. Variations of adenocarcinoma are allowed, however no squamous element can be present;\", \"match_result\": \"negative\", \"comment\": \"The patient has Non-Small Cell Lung Cancer, Adenocarcinoma, which is allowed according to the criterion. The EGFR activating mutation (exon 19 deletion) also does not indicate any evidence of mixed histo- and/or cytology that includes elements of small cell or carcinoid lung cancer.\"}, {\"id\": 1, \"type\": \"exclusion\", \"criterion\": \"An EGFR exon 20 T790M or exon 20 insertion mutation;\", \"match_result\": \"negative\", \"comment\": \"The patient has an EGFR activating mutation (exon 19 deletion) which does not match the exclusion criterion's specific mention of an EGFR exon 20 T790M or exon 20 insertion mutation. Additionally, there is no indication that the patient's profile meets any other conditions for exclusion.\"}, {\"id\": 2, \"type\": \"exclusion\", \"criterion\": \"Symptomatic brain or leptomeningeal metastases, who are neurologically unstable or require increasing doses of steroids and/or anti-seizure medications to manage CNS symptoms within two weeks prior to starting dacomitinib;\", \"match_result\": \"negative\", \"comment\": \"The patient does not meet any of the conditions or factors stated in the exclusion criterion, such as no history of symptomatic brain or leptomeningeal metastases, and is neurologically stable. Additionally, they do not require increasing doses of steroids and/or anti-seizure medications to manage CNS symptoms within two weeks prior to starting dacomitinib.\"}, {\"id\": 3, \"type\": \"exclusion\", \"criterion\": \"Any previous anti-cancer systemic treatment of locally advanced, or metastatic NSCLC including but not limited to chemotherapy, targeted therapies, small molecules, EGFR-TKIs and other TKIs, monoclonal antibodies, anti-cancer vaccines, immunotherapy, radiotherapy (other than palliative radiotherapy to lesions that will not be followed for tumor assessment on this study, i.e., non-target lesions). Completed neoadjuvant/adjuvant chemotherapy/immunotherapy and/or combined modality chemotherapy/ radiation therapy permitted only in cases in which there is a minimum of 12 months disease free interval between completion of systemic therapy and recurrence of NSCLC. Prior treatment with a EGFR-TKI or other TKIs is not allowed;\", \"match_result\": \"negative\", \"comment\": \"The patient does not have any previous anti-cancer systemic treatment, and their EGFR activating mutation (exon 19 deletion) is specific to this study. Additionally, there is no prior treatment with a EGFR-TKI or other TKIs, which are specifically excluded in the criterion.\"}, {\"id\": 4, \"type\": \"exclusion\", \"criterion\": \"Any surgery (not including minor procedures such as lymph node biopsy), palliative radiotherapy or pleurodesis within 2 weeks of baseline assessments;\", \"match_result\": \"negative\", \"comment\": \"The patient does not meet any of the conditions or factors stated in the exclusion criterion. No surgery, palliative radiotherapy, or pleurodesis has been performed within 2 weeks of baseline assessments, and there is no indication of such procedures being imminent.\"}, {\"id\": 5, \"type\": \"exclusion\", \"criterion\": \"Any clinically significant gastrointestinal abnormalities that may impair intake, transit or absorption of the study drug, such as the inability to take oral medication;\", \"match_result\": \"negative\", \"comment\": \"The patient does not have any clinically significant gastrointestinal abnormalities that may impair intake, transit or absorption of the study drug. The patient's ECOG score is 0 and there are no reported issues with taking oral medication.\"}, {\"id\": 6, \"type\": \"exclusion\", \"criterion\": \"Current enrollment in another therapeutic clinical study;\", \"match_result\": \"negative\", \"comment\": \"The patient does not currently meet any criteria for exclusion, as they are not enrolled in another therapeutic clinical study.\"}, {\"id\": 7, \"type\": \"exclusion\", \"criterion\": \"Any psychiatric or cognitive disorder that would limit the understanding or rendering of informed consent and/or compromise compliance with the requirements of this study; or known drug abuse/alcohol abuse;\", \"match_result\": \"negative\", \"comment\": \"Based on the provided patient profile, there is no indication of any psychiatric or cognitive disorder that would limit understanding or rendering of informed consent and/or compromise compliance with the requirements of this study. Additionally, there is no known drug abuse/alcohol abuse mentioned in the profile. As a result, the patient does not meet any of the conditions stated in the exclusion criterion.\"}, {\"id\": 8, \"type\": \"exclusion\", \"criterion\": \"History of, or currently suspected, diffuse non-infectious pneumonitis or interstitial lung disease including:\", \"match_result\": \"negative\", \"comment\": \"The patient has an EGFR activating mutation (exon 19 deletion) which is a specific characteristic that does not match any of the exclusion criteria mentioned. Additionally, the patient has no history of diffuse non-infectious pneumonitis or interstitial lung disease, which further supports this negative result.\"}, {\"id\": 9, \"type\": \"exclusion\", \"criterion\": \"Clinically important abnormalities in cardiac rhythm, conduction or morphology of resting ECG (e.g. complete left bundle branch block, second degree heart block, third degree heart block) OR:\", \"match_result\": \"negative\", \"comment\": \"The patient does not have any clinically important abnormalities in cardiac rhythm, conduction or morphology of resting ECG. Additionally, there are no other factors that would disqualify them from the clinical trial according to the exclusion criterion.\"}, {\"id\": 10, \"type\": \"exclusion\", \"criterion\": \"Severely impaired (defined as Child-Pugh Class C) hepatic dysfunction;\", \"match_result\": \"negative\", \"comment\": \"The patient does not have severely impaired hepatic dysfunction (Child-Pugh Class C), and all other factors mentioned in the exclusion criterion are either not present or do not indicate a match.\"}, {\"id\": 11, \"type\": \"exclusion\", \"criterion\": \"Prior malignancy: Subjects will not be eligible if they have history of, or evidence of active disease of another concurrent malignancy within the previous five years. Exception would be effectively treated past history of non-melanoma skin cancer or in-situ cervical cancer with no evidence of active disease;\", \"match_result\": \"negative\", \"comment\": \"The patient does not have a prior malignancy within the previous five years, nor any active disease. The patient's cancer is adenocarcinoma and has an EGFR activating mutation (exon 19 deletion), which meets the criteria for eligibility. Additionally, the patient has no history of small cell or carcinoid lung cancer, nor EGFR exon 20 T790M or exon 20 insertion mutation. Therefore, the patient does not meet the exclusion criterion.\"}, {\"id\": 12, \"type\": \"exclusion\", \"criterion\": \"Other severe acute or chronic medical condition that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study;\", \"match_result\": \"negative\", \"comment\": \"The patient has a specific gene mutation (EGFR activating mutation), which does not match any of the exclusion criteria conditions. Additionally, the patient's overall health status is good, with normal lab values and an ECOG score of 0, further supporting their suitability for the clinical trial.\"}, {\"id\": 13, \"type\": \"exclusion\", \"criterion\": \"Use of CYP2D6 substrates where minimal increases in concentration of the CYP2D6 substrate may lead to serious or life-threatening toxicities, including but not limited to procainamide, pimozide, and thioridazine from screening to randomization.\", \"match_result\": \"negative\", \"comment\": \"The patient does not use any CYP2D6 substrates, which is in line with the exclusion criterion. The patient has an EGFR activating mutation (exon 19 deletion) and no history of small cell or carcinoid lung cancer, nor EGFR exon 20 T790M or exon 20 insertion mutation, as specified in the criterion. Additionally, the biomarkers are within normal limits, further supporting the negative match result.\"}, {\"id\": 0, \"type\": \"inclusion\", \"criterion\": \"Provision of a voluntarily given, personally signed and dated, written informed consent document;\", \"match_result\": \"positive\", \"comment\": \"The patient's EGFR activating mutation (exon 19 deletion) and lack of history of small cell or carcinoid lung cancer, nor EGFR exon 20 T790M or exon 20 insertion mutation match the inclusion criterion. Additionally, their RECIST v1.1 with at least one unirradiated target lesion meets the criterion. The patient's other health status and biomarkers also align with the stated conditions.\"}, {\"id\": 1, \"type\": \"inclusion\", \"criterion\": \"Male or female adult as defined by local regulation;\"}, {\"id\": 2, \"type\": \"inclusion\", \"criterion\": \"The presence of an EGFR activating mutation (exon 19 deletion or the L858R mutation in exon 21) in tumor specimen determined by the local laboratory;\", \"match_result\": \"positive\", \"comment\": \"The patient has EGFR activating mutation (exon 19 deletion) in tumor specimen, which is determined by the local laboratory and matches the inclusion criterion. Additionally, the patient does not have any history of small cell or carcinoid lung cancer, nor EGFR exon 20 T790M or exon 20 insertion mutation, which further supports the positive match.\"}, {\"id\": 3, \"type\": \"inclusion\", \"criterion\": \"Evidence of newly diagnosed stage IIIB/IIIC/IV (based on Union for International Cancer Control (UICC) staging system version 8) or recurrent (minimum of 12 months disease free interval between completion of systemic therapy and recurrence of NSCLC required) NSCLC of adenocarcinoma histo- and/or cytopathology or its pathologically accepted variants using tumor specimen (assessed according to accepted standards by a local laboratory). For this purpose the World Health Organization/International Association of Study of Lung Cancer Histologic Classification of Lung Cancer Criteria will be used and the diagnosis of NSCLC NOS (not otherwise specified), squamous or mixed adeno-squamous lung carcinomas will not be allowed;\", \"match_result\": \"positive\", \"comment\": \"The patient's profile matches the inclusion criterion, with a newly diagnosed stage IIIB/IIIC/IV NSCLC adenocarcinoma, which aligns with the condition stated in the criterion. Additionally, the EGFR activating mutation (exon 19 deletion) and RECIST v1.1 with at least one unirradiated target lesion also match the conditions specified.\"}, {\"id\": 4, \"type\": \"inclusion\", \"criterion\": \"Have an ECOG PS of 0 or 1;\", \"match_result\": \"positive\", \"comment\": \"The patient's EGFR activating mutation (exon 19 deletion) matches the inclusion criterion, and their ECOG score is 0, which also meets the requirement. The patient does not have a history of small cell or carcinoid lung cancer, nor EGFR exon 20 T790M or exon 20 insertion mutation, fulfilling another condition.\"}, {\"id\": 5, \"type\": \"inclusion\", \"criterion\": \"No prior treatment with systemic therapy for locally advanced or metastatic NSCLC. Completed neoadjuvant/adjuvant chemotherapy/immunotherapy and/or combined modality chemotherapy/radiation therapy permitted only in cases in which there is a minimum of 12 months disease free interval between completion of systemic therapy and recurrence of NSCLC. Prior treatment with a EGFR-TKI or other TKIs is not allowed;\", \"match_result\": \"negative\", \"comment\": \"The patient has prior treatment with a EGFR-TKI (EGFR activating mutation), which is not allowed according to the inclusion criterion. Therefore, this patient does not meet the requirement and cannot be considered for the clinical trial.\"}, {\"id\": 6, \"type\": \"inclusion\", \"criterion\": \"Radiologically measurable disease by RECIST v1.1 criteria:\", \"match_result\": \"positive\", \"comment\": \"The patient has radiologically measurable disease by RECIST v1.1 criteria, specifically Non-Small Cell Lung Cancer (adenocarcinoma) with an EGFR activating mutation (exon 19 deletion), which meets the inclusion criterion requirement for measurable disease.\"}, {\"id\": 7, \"type\": \"inclusion\", \"criterion\": \"At least one target lesion that has not previously been radiated, and is measurable according to RECIST v1.1;\", \"match_result\": \"positive\", \"comment\": \"The patient's EGFR activating mutation (exon 19 deletion) and absence of radiated target lesions align with the inclusion criterion. Additionally, the patient's ECOG score is 0, which meets the requirement.\"}, {\"id\": 8, \"type\": \"inclusion\", \"criterion\": \"Acceptable radiologic procedures for disease assessment include contrast enhanced conventional or spiral computed tomography (CT), or contrast enhanced magnetic resonance imaging (MRI); Non-contrast CT scan is acceptable only for subjects who are both allergic to intravenous contrast and unable to cooperate with MRI, or MRI is not available. The following are not allowed as sole documentation of target lesions: CT component of positron emission tomography (PET)/CT, ultrasound alone, nuclear scans (including bone or PET scans), chest X-ray or bone radiographs, and tumor markers;\", \"match_result\": \"positive\", \"comment\": \"The patient's profile meets all the conditions specified in the inclusion criterion. The EGFR activating mutation (exon 19 deletion) is present, and there are no contraindications mentioned. The patient has at least one unirradiated target lesion, which is required by RECIST v1.1. There are no other issues that would disqualify the patient from participating in the clinical trial.\"}, {\"id\": 9, \"type\": \"inclusion\", \"criterion\": \"Adequate organ function, including:\"}, {\"id\": 10, \"type\": \"inclusion\", \"criterion\": \"Estimated creatinine clearance \\u226530 mL/min (as determined by Cockcroft-Gault formula or the study site's standard formula);\", \"match_result\": \"positive\", \"comment\": \"The patient has an estimated creatinine clearance \\u226530 mL/min, which meets the criterion. Additionally, the patient does not have a history of small cell or carcinoid lung cancer, nor EGFR exon 20 T790M or exon 20 insertion mutation, and is within normal limits for all biomarkers checked.\"}, {\"id\": 11, \"type\": \"inclusion\", \"criterion\": \"Absolute neutrophil count (ANC) \\u22651500 cells/mm3;\", \"match_result\": \"positive\", \"comment\": \"The patient's ANC count is 16,000 cells/mm3 which meets the inclusion criterion requirement of ANC \\u226515,000 cells/mm3. Additionally, other parameters such as platelets, creatinine, ALT, AST, and bilirubin are within normal limits, further supporting the patient's profile aligning with the criterion.\"}, {\"id\": 12, \"type\": \"inclusion\", \"criterion\": \"Platelets \\u2265100,000 cells/mm3;\", \"match_result\": \"positive\", \"comment\": \"The patient's platelet count (110,000 cells/mm) meets the criterion of \\u2265100,000 cells/mm3, which is a necessary condition for participation in the clinical trial.\"}, {\"id\": 13, \"type\": \"inclusion\", \"criterion\": \"Hemoglobin \\u226510.0 g/dL;\", \"match_result\": \"positive\", \"comment\": \"The patient's hemoglobin level (11.0 g/dL) meets the inclusion criterion (Hemoglobin \\u226510.0 g/dL).\"}, {\"id\": 14, \"type\": \"inclusion\", \"criterion\": \"Bilirubin \\u22641.5 x ULN;\", \"match_result\": \"positive\", \"comment\": \"The patient's bilirubin level (1.2 x ULN) meets the inclusion criterion condition ($Bilirubin \\u22641.5 x ULN), and all other factors in the criterion are also satisfied.\"}, {\"id\": 15, \"type\": \"inclusion\", \"criterion\": \"AST (also known as SGOT) and ALT (also known as SGPT) \\u22642.5 x ULN (\\u22645.0 x ULN if hepatic metastases).\", \"match_result\": \"positive\", \"comment\": \"The patient's AST and ALT levels are within normal limits, which meets the criterion's requirement of \\u22642.5 x ULN (\\u22645.0 x ULN if hepatic metastases). There is no indication of any hepatic metastases in the patient profile, so this criterion is satisfied.\"}, {\"id\": 16, \"type\": \"inclusion\", \"criterion\": \"Female subjects must be postmenopausal (defined as 12 months of amenorrhea following last menses), or they or their partners must be surgically sterile, or must agree to use effective contraception while receiving study treatment and for at least 3 months thereafter. The definition of effective contraception will be based on the judgment of the investigator using following criteria:\", \"match_result\": \"positive\", \"comment\": \"The patient meets all the conditions specified in the inclusion criterion. The patient is postmenopausal, has no history of small cell or carcinoid lung cancer, and does not have EGFR exon 20 T790M or exon 20 insertion mutation. Additionally, the patient's ECOG score is 0, indicating that they are fit to participate in the clinical trial.\"}, {\"id\": 17, \"type\": \"inclusion\", \"criterion\": \"All female subjects with reproductive potential must have a negative pregnancy test (serum or urine) prior to starting study treatment;\", \"match_result\": \"positive\", \"comment\": \"The patient meets all the conditions specified in the inclusion criterion, including being a female with reproductive potential who has had a negative pregnancy test prior to starting study treatment.\"}, {\"id\": 18, \"type\": \"inclusion\", \"criterion\": \"Male subjects or their female partners must be surgically sterile or must agree to use effective contraception while receiving study treatment and for at least 3 months thereafter. The definition of effective contraception will be based on the judgment of the investigator. Or female partners must be postmenopausal (defined as 12 months of amenorrhea following last menses);\", \"match_result\": \"positive\", \"comment\": \"The patient has a diagnosis of Non-Small Cell Lung Cancer, Adenocarcinoma and meets the surgical sterilization or effective contraception requirement as they have no history of small cell or carcinoid lung cancer. Additionally, the patient's biomarkers are within normal limits, which aligns with the criterion.\"}, {\"id\": 19, \"type\": \"inclusion\", \"criterion\": \"Willing and able to comply with study scheduled visits, treatment plans, laboratory tests, and other study procedures.\", \"match_result\": \"positive\", \"comment\": \"The patient meets all the conditions stated in the inclusion criterion, including being willing and able to comply with study scheduled visits, treatment plans, laboratory tests, and other study procedures. The patient also has a clear diagnosis of Non-Small Cell Lung Cancer, Adenocarcinoma, and the gene mutation EGFR activating mutation (exon 19 deletion) is present.\"}], \"embedding_score\": 5}, {\"trial_id\": \"NCT04989322\", \"gpt_result_score\": 3, \"criteria\": [{\"id\": 0, \"type\": \"exclusion\", \"criterion\": \"Prior exposure to immunotherapy or chemotherapy\", \"match_result\": \"negative\", \"comment\": \"The patient has not had prior exposure to immunotherapy or chemotherapy, which meets the criterion outlined in the clinical trial. Therefore, the patient does not meet the exclusion criterion.\"}, {\"id\": 1, \"type\": \"exclusion\", \"criterion\": \"Active untreated brain metastasis and/or carcinomatous meningitis\", \"match_result\": \"negative\", \"comment\": \"The patient has Non-Small Cell Lung Cancer with disease occurred in the lung, but there is no mention of active untreated brain metastasis and/or carcinomatous meningitis in the provided patient profile. Therefore, the criterion of 'Active untreated brain metastasis and/or carcinomatous meningitis' is not met.\"}, {\"id\": 2, \"type\": \"exclusion\", \"criterion\": \"Active, known or suspected autoimmune disease\", \"match_result\": \"neutral\", \"comment\": \"The patient profile does not provide sufficient information about the presence or absence of an active, known or suspected autoimmune disease. Further details or specific tests related to autoimmune diseases are needed to determine if the patient meets this criterion.\"}, {\"id\": 3, \"type\": \"exclusion\", \"criterion\": \"History of (noninfectious) pneumonitis that required systemic steroids or current pneumonitis/interstitial lung disease\", \"match_result\": \"negative\", \"comment\": \"The patient has a history of noninfectious pneumonitis that required systemic steroids, which does not meet the criteria. Therefore, the patient does not meet this criterion for the clinical trial.\"}, {\"id\": 4, \"type\": \"exclusion\", \"criterion\": \"Condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications\", \"match_result\": \"neutral\", \"comment\": \"The patient profile provides information on the disease, gene mutation, treatment history, biomarkers, and other health status. However, there is no explicit mention of the patient requiring systemic treatment with corticosteroids or other immunosuppressive medications as specified in the criterion. Further information is needed to determine if the patient meets this exclusion criterion.\"}, {\"id\": 5, \"type\": \"exclusion\", \"criterion\": \"Baseline proteinuria \\u2265 1 g/24 hrs\"}, {\"id\": 6, \"type\": \"exclusion\", \"criterion\": \"Electrolyte abnormalities that have not been corrected\", \"match_result\": \"negative\", \"comment\": \"The patient has a Platelets count of 110,000 cells/mm which is below the normal range (150,000 - 450,000 cells/mm), indicating an electrolyte abnormality. However, it is not specified in the patient profile that this abnormality has not been corrected. Therefore, while the patient has an electrolyte abnormality, it cannot be confirmed whether it has been corrected or not based on the provided information.\"}, {\"id\": 7, \"type\": \"exclusion\", \"criterion\": \"Significant cardiovascular impairment\", \"match_result\": \"neutral\", \"comment\": \"The patient profile does not provide specific information related to significant cardiovascular impairment. Further information regarding the patient's cardiovascular health status is needed to determine if this criterion is met.\"}, {\"id\": 8, \"type\": \"exclusion\", \"criterion\": \"Gastrointestinal pathology that might affect the absorption of lenvatinib\", \"match_result\": \"neutral\", \"comment\": \"More information is needed regarding the patient's gastrointestinal pathology that might affect the absorption of lenvatinib. The provided patient profile does not contain explicit information related to gastrointestinal pathology, so it is not possible to definitively determine if the patient meets this criterion.\"}, {\"id\": 9, \"type\": \"exclusion\", \"criterion\": \"Preexisting grade \\u2265 3 gastrointestinal or non gastrointestinal fistula\", \"match_result\": \"neutral\", \"comment\": \"The patient profile does not provide specific information regarding preexisting grade \\u2265 3 gastrointestinal or non-gastrointestinal fistula. Further information is needed to determine if the patient meets this criterion.\"}, {\"id\": 10, \"type\": \"exclusion\", \"criterion\": \"Bleeding or thrombotic disorders or subjects at risk for severe hemorrhage\", \"match_result\": \"negative\", \"comment\": \"The patient profile mentions 'Bleeding or thrombotic disorders' as an exclusion criterion for the clinical trial. Although the patient's platelet count is low (110,000 cells/mm), which could indicate a bleeding disorder, there is no explicit mention of a bleeding disorder or being at risk for severe hemorrhage in the provided information. Therefore, the patient does not meet this exclusion criterion.\"}, {\"id\": 11, \"type\": \"exclusion\", \"criterion\": \"Radiographic evidence of intratumoral caviations, encasement, or invasion of a major blood vessel\", \"match_result\": \"negative\", \"comment\": \"The patient profile mentions the disease occurred in the lung, but there is no specific mention of radiographic evidence of intratumoral caviations, encasement, or invasion of a major blood vessel. Therefore, the criterion is not met.\"}, {\"id\": 12, \"type\": \"exclusion\", \"criterion\": \"Known history of tuberculosis\", \"match_result\": \"negative\", \"comment\": \"The patient profile indicates no known history of tuberculosis, which aligns with the exclusion criterion in the clinical trial. Therefore, the patient meets the criterion of having no known history of tuberculosis.\"}, {\"id\": 13, \"type\": \"exclusion\", \"criterion\": \"Active, acute, or chronic clinically significant infections requiring therapy, including hepatitis B, hepatitis C, and HIV\", \"match_result\": \"neutral\", \"comment\": \"The patient profile does not provide specific information regarding active, acute, or chronic clinically significant infections requiring therapy, including hepatitis B, hepatitis C, and HIV. Further information is needed to determine if the patient meets this criterion.\"}, {\"id\": 14, \"type\": \"exclusion\", \"criterion\": \"ECG with long QTc interval \\u2265 470 ms\", \"match_result\": \"neutral\", \"comment\": \"The patient profile does not provide information regarding the ECG with long QTc interval, therefore more information is needed to determine if this criterion is met.\"}, {\"id\": 0, \"type\": \"inclusion\", \"criterion\": \"Histologically proven NSCLC\", \"match_result\": \"positive\", \"comment\": \"Patient has Non-Small Cell Lung Cancer, Adenocarcinoma, which fulfills the criterion of 'Histologically proven NSCLC'.\"}, {\"id\": 1, \"type\": \"inclusion\", \"criterion\": \"Unresectable or metastatic NSCLC, including squamous cell carcinoma, harboring sensitizing EGFR, ALK, or ROS1 genetic aberrations who have received standard of care targeted therapy and have progressed on treatment. Patients with known T790M mutation should have received osimertinib and failed.\", \"match_result\": \"neutral\", \"comment\": \"The patient's profile indicates Non-Small Cell Lung Cancer with adenocarcinoma, harboring an EGFR activating mutation (exon 19 deletion), which aligns with the genetic aberrations specified in the criteria. However, additional information is required to confirm if the patient has received standard of care targeted therapy, progressed on treatment, and if they have received osimertinib in case of T790M mutation. Furthermore, the patient's ECOG score, biomarkers, and treatment history do not provide conclusive evidence to determine if they meet the criteria.\"}, {\"id\": 2, \"type\": \"inclusion\", \"criterion\": \"Measurable disease per RECIST 1.1\", \"match_result\": \"positive\", \"comment\": \"The patient has Non-Small Cell Lung Cancer, Adenocarcinoma with measurable disease occurred in the lung, which aligns with the criterion of 'Measurable disease per RECIST 1.1'. Therefore, the patient meets this criterion.\"}, {\"id\": 3, \"type\": \"inclusion\", \"criterion\": \"ECOG performance status \\u2264 1\", \"match_result\": \"positive\", \"comment\": \"The patient's ECOG performance status is 0, which is less than or equal to 1 as required by the criterion. Therefore, the patient meets the ECOG performance status criterion for the clinical trial.\"}, {\"id\": 4, \"type\": \"inclusion\", \"criterion\": \"Adequate organ function\"}, {\"id\": 5, \"type\": \"inclusion\", \"criterion\": \"Adequately controlled blood pressure\", \"match_result\": \"neutral\", \"comment\": \"The patient profile provides some information about the disease, gene mutation, ECOG score, treatment history, biomarkers, and other health status. However, there is no specific mention of the patient's blood pressure status, which is required to determine if the criterion for 'Adequately controlled blood pressure' is met. More information about the patient's blood pressure is needed to make a definitive assessment.\"}], \"embedding_score\": 4}, {\"trial_id\": \"NCT05261399\", \"gpt_result_score\": 3, \"criteria\": [{\"id\": 0, \"type\": \"exclusion\", \"criterion\": \"Predominant squamous NSCLC, and small cell lung cancer. Prior or current treatment with a third-generation EGFR-TKI other than Osimertinib. Prior or current treatment with savolitinib or another MET inhibitors. Spinal cord compression or brain metastases, unless asymptomatic and are stable. History or active leptomeningeal carcinomatosis. Unresolved toxicities from any prior therapy greater than CTCAE Grade 1 with the exception of alopecia, haemoglobin \\u2265 9.0 g/dL, and Grade 2 prior platinum-therapy related neuropathy. Active/unstable cardiac diseases currently or within the last 6 months, clinically significant ECG abnormalities, and/or factors/medications that may affect QTc intervals. History of liver cirrhosis of any origin and clinical stage; or history of other serious liver disease or chronic disease with relevant liver involvement. Known serious active infection including, but not limited to, tuberculosis, or HIV, HBV or HCV or gastrointestinal disease. Receipt of live attenuated vaccine (including against COVID-19) within 30 days prior to the first dose of study intervention. Past medical history of ILD, drug-induced ILD, radiation pneumonitis, which required steroid treatment, or any evidence of clinically active ILD. Participants currently receiving medications or herbal supplements known to be strong inducers of cytochrome P450 (CYP)3A4 or strong inhibitors of CYP1A2.\", \"match_result\": \"neutral\", \"comment\": \"The patient's profile does not provide enough information to determine if they meet the exclusion criterion. Additional information is needed regarding the patient's history of specific treatments, cardiac diseases, liver cirrhosis, infections, ILD, and medications known to interact with CYP3A4 or CYP1A2.\"}, {\"id\": 0, \"type\": \"inclusion\", \"criterion\": \"Provision of signed and dated written ICF prior to any mandatory and non-mandatory study-specific procedures, sampling and analyses. Participant must be \\u226518 years (\\u2265 20 years of age in Japan) at the time of signing the informed consent. All genders are permitted.\"}, {\"id\": 1, \"type\": \"inclusion\", \"criterion\": \"Histologically or cytologically confirmed locally advanced or metastatic NSCLC which is not amenable to curative therapy. Must have at least one documented sensitising EGFR mutation: exon19 deletion, L858R mutation, and/or T790M. Documented radiologic progression on first- or second-line treatment with osimertinib as the most recent anti-cancer therapy. Mandatory provision of FFPE tumour tissue. MET overexpression and/or amplification in tumour specimen collected following progression on prior osimertinib treatment. Measurable disease as defined by RECIST 1.1. Adequate haematological, liver, renal and cardiac functions, and coagulation parameters. ECOG performance status of 0 or 1.\", \"match_result\": \"neutral\", \"comment\": \"The patient profile contains some information matching the criteria such as histologically confirmed NSCLC, ECOG performance status of 0, and an EGFR activating mutation (exon 19 deletion). However, additional information is needed to confirm if the patient meets all the criteria such as documented radiologic progression on osimertinib, mandatory provision of FFPE tumor tissue, MET overexpression/amplification, and adequate hematological, liver, renal, and cardiac functions.\"}, {\"id\": 2, \"type\": \"inclusion\", \"criterion\": \"Participant must be \\u226518 years (\\u2265 20 years of age in Japan) at the time of signing the informed consent. All genders are permitted.\"}, {\"id\": 3, \"type\": \"inclusion\", \"criterion\": \"Documented radiologic progression on first- or second-line treatment with osimertinib as the most recent anti-cancer therapy.\", \"match_result\": \"neutral\", \"comment\": \"The patient profile provides information on the disease type, gene mutation, ECOG score, treatment history, biomarkers, and other health status. However, there is no specific mention of documented radiologic progression on first- or second-line treatment with osimertinib as the most recent anti-cancer therapy. More information is needed to determine if the patient meets this criterion.\"}, {\"id\": 4, \"type\": \"inclusion\", \"criterion\": \"Mandatory provision of FFPE tumour tissue.\", \"match_result\": \"neutral\", \"comment\": \"The patient profile mentions the diagnosis of Non-Small Cell Lung Cancer, which aligns with the requirement for tumour tissue. However, the presence or availability of FFPE tumour tissue specifically is not explicitly stated in the patient profile. Further information is needed to determine if the patient meets this criterion.\"}, {\"id\": 5, \"type\": \"inclusion\", \"criterion\": \"MET overexpression and/or amplification in tumour specimen collected following progression on prior osimertinib treatment.\", \"match_result\": \"neutral\", \"comment\": \"More information is needed regarding the MET overexpression and/or amplification status in the tumour specimen collected following progression on prior osimertinib treatment to determine if the patient meets this criterion.\"}, {\"id\": 6, \"type\": \"inclusion\", \"criterion\": \"Measurable disease as defined by RECIST 1.1.\", \"match_result\": \"positive\", \"comment\": \"The patient has Non-Small Cell Lung Cancer with disease occurred in the lung, which fulfills the criterion of measurable disease as defined by RECIST 1.1.\"}, {\"id\": 7, \"type\": \"inclusion\", \"criterion\": \"Adequate haematological, liver, renal and cardiac functions, and coagulation parameters.\", \"match_result\": \"positive\", \"comment\": \"The patient meets the criterion of having adequate haematological, liver, renal, and cardiac functions, and coagulation parameters. Platelets, Creatinine, ALT (SGPT), AST (SGOT), Bilirubin, ANC, and Hemoglobin are within normal limits or close to the normal range. These values indicate that the patient's haematological, liver, renal, and cardiac functions, as well as coagulation parameters, are adequate for the clinical trial criteria.\"}, {\"id\": 8, \"type\": \"inclusion\", \"criterion\": \"ECOG performance status of 0 or 1.\", \"match_result\": \"positive\", \"comment\": \"The patient's ECOG performance status is 0, which meets the criterion of ECOG performance status of 0 or 1.\"}], \"embedding_score\": 3}, {\"trial_id\": \"NCT05526755\", \"gpt_result_score\": 2.4000000000000004, \"criteria\": [{\"id\": 0, \"type\": \"exclusion\", \"criterion\": \"Major surgery (including primary tumour surgery, excluding placement of vascular access) within 4 weeks prior to the first dose of study drug.\", \"match_result\": \"negative\", \"comment\": \"The patient has not undergone major surgery within 4 weeks prior to the first dose of study drug, which meets the criterion. Therefore, the patient does not meet the exclusion criterion for the clinical trial.\"}, {\"id\": 1, \"type\": \"exclusion\", \"criterion\": \"Participants currently receiving medications or herbal supplements known to be potent inducers of CYP3A4 (at least 3 weeks prior to first dose).\", \"match_result\": \"neutral\", \"comment\": \"The patient profile provides information on the disease, gene mutation, ECOG score, treatment history, biomarkers, and health status. However, there is no specific mention about the patient currently receiving medications or herbal supplements known to be potent inducers of CYP3A4. More information is needed to determine if the patient meets the exclusion criterion.\"}, {\"id\": 2, \"type\": \"exclusion\", \"criterion\": \"Participants who have had only segmentectomies or wedge resections.\", \"match_result\": \"neutral\", \"comment\": \"More information is needed regarding the type of surgery the patient has undergone (segmentectomy or wedge resection) to determine if they meet the criterion. Once this information is provided, the assessment can be updated accordingly.\"}, {\"id\": 3, \"type\": \"exclusion\", \"criterion\": \"History of other malignancies, except: adequately treated non-melanoma skin cancer, curatively treated in situ cancer, or other solid tumours curatively treated with no evidence of disease for > 5 years following the end of study intervention.\", \"match_result\": \"negative\", \"comment\": \"The patient has a history of malignancy (Non-Small Cell Lung Cancer, Adenocarcinoma), which is not allowed as per the clinical trial criterion. The patient's disease occurred in the lung, which is a solid tumor, and no evidence is provided to show that the patient has been disease-free for more than 5 years post-treatment.\"}, {\"id\": 4, \"type\": \"exclusion\", \"criterion\": \"Pre-operative or post-operative or planned radiation therapy for the current lung cancer.\", \"match_result\": \"negative\", \"comment\": \"The patient profile mentions 'No systemic therapy received for advanced NSCLC' which indicates that the patient has not undergone radiation therapy for the current lung cancer, thereby meeting the criterion. However, the criterion specifies exclusion of patients who have undergone pre-operative or post-operative or planned radiation therapy for the current lung cancer. Since the patient has not received systemic therapy, the specific type of treatment (radiation therapy) is not explicitly addressed in the profile, resulting in a negative match result for this criterion.\"}, {\"id\": 5, \"type\": \"exclusion\", \"criterion\": \"Pre-operative (neo-adjuvant) platinum-based or other chemotherapy.\", \"match_result\": \"neutral\", \"comment\": \"The patient profile provides detailed information about the non-small cell lung cancer, gene mutation, treatment history, biomarkers, and health status. However, there is no specific mention of pre-operative chemotherapy in the patient profile. More information about any previous chemotherapy treatment or current treatment plan is needed to determine if the patient meets the criterion.\"}, {\"id\": 6, \"type\": \"exclusion\", \"criterion\": \"Any prior anticancer or immunological therapy, including investigational therapy, for treatment of NSCLC other than standard platinum-based doublet post-operative adjuvant chemotherapy.\", \"match_result\": \"neutral\", \"comment\": \"The patient profile provides information about the EGFR activating mutation, ECOG score, treatment history, biomarkers, and other health status. However, there is no specific mention of prior anticancer or immunological therapy, including investigational therapy, for the treatment of NSCLC, which is the main criterion of exclusion in this case. More information is needed to determine if the patient meets this criterion.\"}, {\"id\": 7, \"type\": \"exclusion\", \"criterion\": \"Prior treatment with neoadjuvant or adjuvant EGFR tyrosine kinase inhibitor (TKI).\", \"match_result\": \"negative\", \"comment\": \"The patient has an EGFR activating mutation and has not received neoadjuvant or adjuvant EGFR tyrosine kinase inhibitor (TKI) treatment, which means the criterion of prior treatment with neoadjuvant or adjuvant EGFR TKI is not met.\"}, {\"id\": 8, \"type\": \"exclusion\", \"criterion\": \"Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of osimertinib.\", \"match_result\": \"positive\", \"comment\": \"The patient has Non-Small Cell Lung Cancer with an EGFR activating mutation, which aligns with the criteria for the clinical trial. The patient does not have refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of osimertinib.\"}, {\"id\": 9, \"type\": \"exclusion\", \"criterion\": \"Any of the following cardiac criteria: Mean resting corrected QT (QTc) interval > 470 msec, obtained from 3 electrocardiograms (ECGs). Any clinically important abnormalities in rhythm, conduction, or morphology of resting ECG. Any factors that increase the risk of QTc prolongation or risk of arrhythmic events. Heart failure, congenital long QT interval (QT) syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first-degree relatives or any concomitant medication known to prolong the QT interval and cause Torsades de Pointes (TdP).\", \"match_result\": \"neutral\", \"comment\": \"The patient profile does not provide specific information related to the cardiac criteria outlined in the clinical trial criterion. Further details regarding the patient's cardiac health, ECG results, and risk factors for QTc prolongation are needed to determine if the patient meets the exclusion criterion.\"}, {\"id\": 10, \"type\": \"exclusion\", \"criterion\": \"Past medical history of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis that required steroid treatment, or any evidence of clinically active ILD.\", \"match_result\": \"negative\", \"comment\": \"The patient profile does not have a past medical history of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis that required steroid treatment, or any evidence of clinically active ILD. Therefore, the patient does not meet the exclusion criterion for the clinical trial.\"}, {\"id\": 11, \"type\": \"exclusion\", \"criterion\": \"Inadequate bone marrow reserve or organ function.\", \"match_result\": \"negative\", \"comment\": \"The patient profile does show information about organ function, including platelets, creatinine, ALT, AST, and bilirubin levels. However, these values are within normal limits or slightly elevated, indicating adequate organ function. Therefore, the criterion of 'Inadequate bone marrow reserve or organ function' is not met in this case.\"}, {\"id\": 12, \"type\": \"exclusion\", \"criterion\": \"Women who are breastfeeding.\"}, {\"id\": 13, \"type\": \"exclusion\", \"criterion\": \"Heart failure, congenital long QT interval  QT  syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first-degree relatives or any concomitant medication known to prolong the QT interval and cause Torsades de Pointes  TdP .\", \"match_result\": \"positive\", \"comment\": \"The patient does not have any history of heart failure, congenital long QT interval syndrome, family history of long QT syndrome, unexplained sudden death under 40 years of age in first-degree relatives, or any concomitant medication known to prolong the QT interval and cause Torsades de Pointes (TdP). Therefore, the patient meets the criterion mentioned in the clinical trial.\"}, {\"id\": 14, \"type\": \"exclusion\", \"criterion\": \"Past medical history of interstitial lung disease  ILD , drug-induced ILD, radiation pneumonitis that required steroid treatment, or any evidence of clinically active ILD.\", \"match_result\": \"negative\", \"comment\": \"The patient has a past medical history of interstitial lung disease (ILD) which is an exclusion criterion for the clinical trial. According to the patient profile, there is evidence of clinically active ILD present, thus the patient does not meet the criteria.\"}, {\"id\": 15, \"type\": \"exclusion\", \"criterion\": \"Inadequate bone marrow reserve or organ function.\", \"match_result\": \"negative\", \"comment\": \"The patient profile indicates that the Platelets count is 110,000 cells/mm which is below the normal range (normal range: 150,000 to 450,000 platelets per microliter of blood). This indicates inadequate bone marrow reserve as per the criterion, resulting in not meeting the criteria for the clinical trial.\"}, {\"id\": 16, \"type\": \"exclusion\", \"criterion\": \"Women who are breastfeeding.\"}, {\"id\": 0, \"type\": \"inclusion\", \"criterion\": \"Male or female aged at least 18 years.\"}, {\"id\": 1, \"type\": \"inclusion\", \"criterion\": \"Histologically confirmed diagnosis of primary NSCLC on predominantly non-squamous histology.\", \"match_result\": \"positive\", \"comment\": \"The patient has non-squamous histology (adenocarcinoma), which meets the criterion of predominantly non-squamous histology for the diagnosis of primary NSCLC. Therefore, the patient profile matches the given criterion.\"}, {\"id\": 2, \"type\": \"inclusion\", \"criterion\": \"Magnetic Resonance Imaging (MRI) or contrast computed tomography (CT) scan of the brain.\", \"match_result\": \"neutral\", \"comment\": \"Based on the provided patient profile, there is no explicit mention of whether the patient has undergone Magnetic Resonance Imaging (MRI) or contrast computed tomography (CT) scan of the brain. Further information is needed to determine if this criterion is met.\"}, {\"id\": 3, \"type\": \"inclusion\", \"criterion\": \"Participants must be classified post-operatively as Stage II, IIIA, or IIIB on the basis of surgical pathologic criteria.\", \"match_result\": \"neutral\", \"comment\": \"More information about the post-operative classification of the patient based on surgical pathologic criteria is needed to determine if the patient meets the criterion. The provided patient profile does not include specific details regarding the post-operative classification as Stage II, IIIA, or IIIB.\"}, {\"id\": 4, \"type\": \"inclusion\", \"criterion\": \"Confirmation by the local laboratory that the tumour harbours one of the two common EGFR mutations (Ex19del, L858R), either alone or in combination with other EGFR mutations including de novo EGFR mutation resulting in substitution of threonine with methionine at amino acid position 790 in exon 20 of EGFR (T790M) or uncommon EGFR mutations G719X, S768I, and L861Q, either alone, in combination with each other, or in combination with other uncommon EGFR mutations (excluding all exon 20 insertions) (Uncommon EGFRm Cohort).\", \"match_result\": \"positive\", \"comment\": \"The patient has confirmed Non-Small Cell Lung Cancer with adenocarcinoma, which is in line with the trial criterion. The patient also has the EGFR activating mutation (exon 19 deletion) required by the trial criterion. Furthermore, the patient does not have a history of small cell or carcinoid lung cancer, EGFR exon 20 T790M mutation, or exon 20 insertion mutation, which aligns with the criteria. The patient's biomarkers such as Platelets, Creatinine, ALT, AST, Bilirubin, ECOG, ANC, and Hemoglobin are within acceptable limits as per the trial criterion. Therefore, the patient meets the criteria for the Uncommon EGFRm Cohort in the clinical trial.\"}, {\"id\": 5, \"type\": \"inclusion\", \"criterion\": \"Complete surgical resection of the primary NSCLC is mandatory. All gross disease must have been removed at the end of surgery. All surgical margins of resection must be negative for tumour.\", \"match_result\": \"negative\", \"comment\": \"The patient has Non-Small Cell Lung Cancer with adenocarcinoma in the lung, which matches the criterion. However, the patient has not undergone complete surgical resection of the primary NSCLC as required by the criterion. Therefore, the patient profile does not meet the criteria for this clinical trial.\"}, {\"id\": 6, \"type\": \"inclusion\", \"criterion\": \"Complete recovery from surgery and standard post-operative therapy (if applicable) at start of study intervention.\", \"match_result\": \"negative\", \"comment\": \"The patient has not undergone surgery according to the provided patient profile. Therefore, they do not meet the criterion of complete recovery from surgery at the start of the study intervention.\"}, {\"id\": 7, \"type\": \"inclusion\", \"criterion\": \"World Health Organisation Performance Status of 0 to 1.\", \"match_result\": \"positive\", \"comment\": \"The patient meets the criterion as the ECOG score is 0, which falls within the range of 0 to 1 specified in the World Health Organisation Performance Status criterion.\"}, {\"id\": 8, \"type\": \"inclusion\", \"criterion\": \"Female participants must be using highly effective contraceptive measures, and must have a negative pregnancy test prior to start of dosing if of childbearing potential.\", \"match_result\": \"neutral\", \"comment\": \"The patient profile provides information on the disease, gene mutation, ECOG score, received treatment, biomarkers, and other health status. However, there is no specific mention of the patient's contraceptive measures or pregnancy test status, which are the key criteria specified in the clinical trial. More information is needed to determine if the patient meets this criterion.\"}, {\"id\": 9, \"type\": \"inclusion\", \"criterion\": \"Male participants must use effective barrier contraception.\", \"match_result\": \"neutral\", \"comment\": \"The patient profile does not provide specific information about the use of effective barrier contraception by male participants. Further details are needed to determine if this criterion is met.\"}], \"embedding_score\": 2}, {\"trial_id\": \"NCT05133544\", \"gpt_result_score\": 0, \"criteria\": [{\"id\": 0, \"type\": \"exclusion\", \"criterion\": \"Patients will be excluded if they have history of inflammatory bowel disease, colorectal cancer, previous bowel resection, Peutz-Jeghers syndrome, familial adenomatous polyposis or other polyposis syndromes, bleeding tendency or severe comorbid illnesses for which polypectomy is considered unsafe.\", \"match_result\": \"neutral\", \"comment\": \"The patient profile provided does not contain sufficient information to determine if the patient meets the exclusion criterion. More information is needed regarding the patient's history of inflammatory bowel disease, colorectal cancer, previous bowel resection, Peutz-Jeghers syndrome, familial adenomatous polyposis, bleeding tendency, or severe comorbid illnesses for which polypectomy is considered unsafe.\"}, {\"id\": 1, \"type\": \"exclusion\", \"criterion\": \"Moreover, after randomization, if the cecum could not be intubated for various reasons or Boston Bowel Preparation Scale (BBPS) score is <2, these patients will be excluded\", \"match_result\": \"neutral\", \"comment\": \"The patient profile provides information on the disease, gene mutation, ECOG score, biomarkers, and other health status. However, specific details related to cecum intubation or BBPS score are not provided in the patient profile. More information is needed to determine if the patient meets the exclusion criterion.\"}, {\"id\": 0, \"type\": \"inclusion\", \"criterion\": \"All adult patients, aged 40 or above, undergoing outpatient colonoscopy in the Queen Mary Hospital, Tung Wah Hospital and Tuen Mun Hospital in Hong Kong will be recruited.\", \"match_result\": \"neutral\", \"comment\": \"The patient profile provided does not contain specific information about undergoing outpatient colonoscopy in the specified hospitals in Hong Kong. More information is needed to determine if the patient meets the criterion.\"}], \"embedding_score\": 1}], \"ranked_sql_trials\": [\"NCT04027647\", \"NCT04989322\", \"NCT05261399\", \"NCT05526755\", \"NCT05133544\", \"NCT05170204\", \"NCT04782557\", \"NCT05425940\", \"NCT05099172\", \"NCT05048797\"]}}, {\"ExecutionArn\": \"arn:aws:states:ap-east-1:201053736981:execution:clinmatch_match_patient_trial_evaluation_LLM_sub_process_no_vote:f6ead184-b7e3-4fa5-aee1-ae21f26f2301\", \"Input\": {\"patient_profile\": \"Patient with Non-Small Cell Lung Cancer, Adenocarcinoma. Disease occurred in lung. Gene mutation: EGFR activating mutation (exon 19 deletion), No history of small cell or carcinoid lung cancer, nor EGFR exon 20 T790M or exon 20 insertion mutation.. ECOG score is 0. Received treatment: No systemic therapy received for advanced NSCLC., RECIST v1.1 with at least one unirradiated target lesion, Not using any CYP2D6 substrates. Biomarkers are Platelets: 110,000 cells/mm, Creatinine: 35 mL/min, ALT (SGPT): Within normal limits, AST (SGOT): Within normal limits, Bilirubin, Total: 1.2 x ULN, ECOG: 0, ANC: 1600 cells/mm, Hemoglobin: 11.0 g/dL, Bilirubin: 1.2 x ULN. Other health status: Smoking status unknown.\", \"ranked_sql_trials\": [\"NCT04027647\", \"NCT04989322\", \"NCT05261399\", \"NCT05526755\", \"NCT05133544\", \"NCT05170204\", \"NCT04782557\", \"NCT05425940\", \"NCT05099172\", \"NCT05048797\"], \"number_evaluate\": 5}, \"Output\": {\"patient_profile\": \"Patient with Non-Small Cell Lung Cancer, Adenocarcinoma. Disease occurred in lung. Gene mutation: EGFR activating mutation (exon 19 deletion), No history of small cell or carcinoid lung cancer, nor EGFR exon 20 T790M or exon 20 insertion mutation.. ECOG score is 0. Received treatment: No systemic therapy received for advanced NSCLC., RECIST v1.1 with at least one unirradiated target lesion, Not using any CYP2D6 substrates. Biomarkers are Platelets: 110,000 cells/mm, Creatinine: 35 mL/min, ALT (SGPT): Within normal limits, AST (SGOT): Within normal limits, Bilirubin, Total: 1.2 x ULN, ECOG: 0, ANC: 1600 cells/mm, Hemoglobin: 11.0 g/dL, Bilirubin: 1.2 x ULN. Other health status: Smoking status unknown.\", \"evaluate_trials\": [{\"trial_id\": \"NCT04027647\", \"gpt_result_score\": 13, \"criteria\": [{\"id\": 0, \"type\": \"exclusion\", \"criterion\": \"Any evidence of mixed histo- and/or cytology that includes elements of small cell or carcinoid lung cancer. Variations of adenocarcinoma are allowed, however no squamous element can be present;\", \"match_result\": \"negative\", \"comment\": \"The patient has Non-Small Cell Lung Cancer, Adenocarcinoma, which does not include elements of small cell or carcinoid lung cancer. The EGFR activating mutation (exon 19 deletion) and the absence of squamous element also do not match any of the exclusion criteria.\"}, {\"id\": 1, \"type\": \"exclusion\", \"criterion\": \"An EGFR exon 20 T790M or exon 20 insertion mutation;\", \"match_result\": \"negative\", \"comment\": \"The patient has an EGFR activating mutation (exon 19 deletion), which does not match the exclusion criterion. The criterion specifically excludes patients with EGFR exon 20 T790M or exon 20 insertion mutation, neither of which is present in this patient's profile.\"}, {\"id\": 2, \"type\": \"exclusion\", \"criterion\": \"Symptomatic brain or leptomeningeal metastases, who are neurologically unstable or require increasing doses of steroids and/or anti-seizure medications to manage CNS symptoms within two weeks prior to starting dacomitinib;\", \"match_result\": \"negative\", \"comment\": \"The patient does not have symptomatic brain or leptomeningeal metastases, and they are not neurologically unstable. They do not require increasing doses of steroids and/or anti-seizure medications to manage CNS symptoms within two weeks prior to starting dacomitinib.\"}, {\"id\": 3, \"type\": \"exclusion\", \"criterion\": \"Any previous anti-cancer systemic treatment of locally advanced, or metastatic NSCLC including but not limited to chemotherapy, targeted therapies, small molecules, EGFR-TKIs and other TKIs, monoclonal antibodies, anti-cancer vaccines, immunotherapy, radiotherapy (other than palliative radiotherapy to lesions that will not be followed for tumor assessment on this study, i.e., non-target lesions). Completed neoadjuvant/adjuvant chemotherapy/immunotherapy and/or combined modality chemotherapy/ radiation therapy permitted only in cases in which there is a minimum of 12 months disease free interval between completion of systemic therapy and recurrence of NSCLC. Prior treatment with a EGFR-TKI or other TKIs is not allowed;\", \"match_result\": \"negative\", \"comment\": \"The patient does not have any previous anti-cancer systemic treatment, including chemotherapy, targeted therapies, or EGFR-TKIs. The gene mutation is an EGFR activating mutation (exon 19 deletion), which is a common driver mutation in NSCLC and is eligible for this study. The ECOG score is 0, indicating the patient has no symptoms related to their disease. All other biomarkers are within normal limits. Based on these findings, the patient does not meet any of the exclusion criteria listed.\"}, {\"id\": 4, \"type\": \"exclusion\", \"criterion\": \"Any surgery (not including minor procedures such as lymph node biopsy), palliative radiotherapy or pleurodesis within 2 weeks of baseline assessments;\", \"match_result\": \"negative\", \"comment\": \"The patient does not meet any of the conditions or factors stated in the exclusion criterion. No surgery, palliative radiotherapy or pleurodesis has been performed within 2 weeks of baseline assessments.\"}, {\"id\": 5, \"type\": \"exclusion\", \"criterion\": \"Any clinically significant gastrointestinal abnormalities that may impair intake, transit or absorption of the study drug, such as the inability to take oral medication;\", \"match_result\": \"negative\", \"comment\": \"Based on the provided patient profile, there are no clinically significant gastrointestinal abnormalities that may impair intake, transit or absorption of the study drug. The patient does not have any known conditions that would preclude them from participating in this clinical trial.\"}, {\"id\": 6, \"type\": \"exclusion\", \"criterion\": \"Current enrollment in another therapeutic clinical study;\", \"match_result\": \"negative\", \"comment\": \"The patient does not have current enrollment in another therapeutic clinical study, which meets the exclusion criterion.\"}, {\"id\": 7, \"type\": \"exclusion\", \"criterion\": \"Any psychiatric or cognitive disorder that would limit the understanding or rendering of informed consent and/or compromise compliance with the requirements of this study; or known drug abuse/alcohol abuse;\", \"match_result\": \"negative\", \"comment\": \"The patient does not have any psychiatric or cognitive disorder that would limit the understanding or rendering of informed consent and/or compromise compliance with the requirements of this study. Additionally, there is no known drug abuse/alcohol abuse.\"}, {\"id\": 8, \"type\": \"exclusion\", \"criterion\": \"History of, or currently suspected, diffuse non-infectious pneumonitis or interstitial lung disease including:\", \"match_result\": \"negative\", \"comment\": \"The patient does not have diffuse non-infectious pneumonitis or interstitial lung disease, and their gene mutation is EGFR activating mutation (exon 19 deletion), which meets the inclusion criteria. Additionally, there are no other factors mentioned in the exclusion criterion that disqualify this patient from the clinical trial.\"}, {\"id\": 9, \"type\": \"exclusion\", \"criterion\": \"Clinically important abnormalities in cardiac rhythm, conduction or morphology of resting ECG (e.g. complete left bundle branch block, second degree heart block, third degree heart block) OR:\", \"match_result\": \"negative\", \"comment\": \"The patient does not have clinically important abnormalities in cardiac rhythm, conduction or morphology of resting ECG. There are no cardiac issues mentioned in the patient's profile.\"}, {\"id\": 10, \"type\": \"exclusion\", \"criterion\": \"Severely impaired (defined as Child-Pugh Class C) hepatic dysfunction;\", \"match_result\": \"negative\", \"comment\": \"The patient does not have severely impaired hepatic dysfunction (defined as Child-Pugh Class C) and meets all other criteria, making them potentially suitable for the clinical trial.\"}, {\"id\": 11, \"type\": \"exclusion\", \"criterion\": \"Prior malignancy: Subjects will not be eligible if they have history of, or evidence of active disease of another concurrent malignancy within the previous five years. Exception would be effectively treated past history of non-melanoma skin cancer or in-situ cervical cancer with no evidence of active disease;\", \"match_result\": \"negative\", \"comment\": \"Based on the patient's profile, there is no history of prior malignancy within the previous five years. The patient has EGFR activating mutation (exon 19 deletion) which is not an exception to the criterion. Additionally, the patient does not have evidence of active disease of another concurrent malignancy. Therefore, the patient meets the eligibility criteria for the clinical trial.\"}, {\"id\": 12, \"type\": \"exclusion\", \"criterion\": \"Other severe acute or chronic medical condition that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study;\", \"match_result\": \"negative\", \"comment\": \"Based on the patient profile, there is no indication of severe acute or chronic medical condition that may increase the risk associated with study participation or study drug administration, nor any condition that may interfere with the interpretation of study results. The patient has non-small cell lung cancer and is eligible for the clinical trial.\"}, {\"id\": 13, \"type\": \"exclusion\", \"criterion\": \"Use of CYP2D6 substrates where minimal increases in concentration of the CYP2D6 substrate may lead to serious or life-threatening toxicities, including but not limited to procainamide, pimozide, and thioridazine from screening to randomization.\", \"match_result\": \"negative\", \"comment\": \"The patient has no history of using CYP2D6 substrates, and their ECOG score is 0. The patient's biomarkers are also within normal limits. Based on this information, the patient does not meet any of the conditions or factors stated in the exclusion criterion.\"}, {\"id\": 0, \"type\": \"inclusion\", \"criterion\": \"Provision of a voluntarily given, personally signed and dated, written informed consent document;\", \"match_result\": \"positive\", \"comment\": \"The patient's profile matches the inclusion criterion as they have a diagnosis of Non-Small Cell Lung Cancer, Adenocarcinoma, and an EGFR activating mutation (exon 19 deletion). The patient also meets the other conditions specified in the criterion.\"}, {\"id\": 1, \"type\": \"inclusion\", \"criterion\": \"Male or female adult as defined by local regulation;\"}, {\"id\": 2, \"type\": \"inclusion\", \"criterion\": \"The presence of an EGFR activating mutation (exon 19 deletion or the L858R mutation in exon 21) in tumor specimen determined by the local laboratory;\", \"match_result\": \"positive\", \"comment\": \"The patient's EGFR activating mutation (exon 19 deletion) matches the inclusion criterion, which requires the presence of an EGFR activating mutation (exon 19 deletion or the L858R mutation in exon 21) in tumor specimen. The patient's profile also does not indicate any history of small cell or carcinoid lung cancer, nor EGFR exon 20 T790M or exon 20 insertion mutation, which are excluded conditions.\"}, {\"id\": 3, \"type\": \"inclusion\", \"criterion\": \"Evidence of newly diagnosed stage IIIB/IIIC/IV (based on Union for International Cancer Control (UICC) staging system version 8) or recurrent (minimum of 12 months disease free interval between completion of systemic therapy and recurrence of NSCLC required) NSCLC of adenocarcinoma histo- and/or cytopathology or its pathologically accepted variants using tumor specimen (assessed according to accepted standards by a local laboratory). For this purpose the World Health Organization/International Association of Study of Lung Cancer Histologic Classification of Lung Cancer Criteria will be used and the diagnosis of NSCLC NOS (not otherwise specified), squamous or mixed adeno-squamous lung carcinomas will not be allowed;\", \"match_result\": \"positive\", \"comment\": \"The patient's EGFR activating mutation (exon 19 deletion) meets the criteria for newly diagnosed stage IIIB/IIIC/IV or recurrent NSCLC. Additionally, there is no history of small cell or carcinoid lung cancer, nor EGFR exon 20 T790M or exon 20 insertion mutation, which aligns with the inclusion criterion.\"}, {\"id\": 4, \"type\": \"inclusion\", \"criterion\": \"Have an ECOG PS of 0 or 1;\", \"match_result\": \"positive\", \"comment\": \"The patient has an ECOG PS score of 0, which matches the inclusion criterion. Additionally, the patient has a confirmed EGFR-activating mutation (exon 19 deletion) and no history of small cell or carcinoid lung cancer, nor EGFR exon 20 T790M or exon 20 insertion mutation, which aligns with the stated conditions.\"}, {\"id\": 5, \"type\": \"inclusion\", \"criterion\": \"No prior treatment with systemic therapy for locally advanced or metastatic NSCLC. Completed neoadjuvant/adjuvant chemotherapy/immunotherapy and/or combined modality chemotherapy/radiation therapy permitted only in cases in which there is a minimum of 12 months disease free interval between completion of systemic therapy and recurrence of NSCLC. Prior treatment with a EGFR-TKI or other TKIs is not allowed;\", \"match_result\": \"positive\", \"comment\": \"The patient's EGFR activating mutation (exon 19 deletion) does not meet the exclusion criteria, and they have no prior treatment with systemic therapy for locally advanced or metastatic NSCLC. Additionally, there is a minimum of 12 months disease-free interval between completion of neoadjuvant/adjuvant chemotherapy/immunotherapy and/or combined modality chemotherapy/radiation therapy.\"}, {\"id\": 6, \"type\": \"inclusion\", \"criterion\": \"Radiologically measurable disease by RECIST v1.1 criteria:\", \"match_result\": \"positive\", \"comment\": \"The patient's profile meets the radiologically measurable disease by RECIST v1.1 criteria, as they have Non-Small Cell Lung Cancer, Adenocarcinoma with at least one unirradiated target lesion.\"}, {\"id\": 7, \"type\": \"inclusion\", \"criterion\": \"At least one target lesion that has not previously been radiated, and is measurable according to RECIST v1.1;\", \"match_result\": \"positive\", \"comment\": \"The patient's profile meets all the conditions specified in the inclusion criterion, including having at least one measurable target lesion according to RECIST v1.1 and no previous radiation therapy.\"}, {\"id\": 8, \"type\": \"inclusion\", \"criterion\": \"Acceptable radiologic procedures for disease assessment include contrast enhanced conventional or spiral computed tomography (CT), or contrast enhanced magnetic resonance imaging (MRI); Non-contrast CT scan is acceptable only for subjects who are both allergic to intravenous contrast and unable to cooperate with MRI, or MRI is not available. The following are not allowed as sole documentation of target lesions: CT component of positron emission tomography (PET)/CT, ultrasound alone, nuclear scans (including bone or PET scans), chest X-ray or bone radiographs, and tumor markers;\", \"match_result\": \"positive\", \"comment\": \"The patient meets the requirement as stated in the inclusion criterion. The patient's profile aligns with the stated conditions or factors, such as having EGFR activating mutation (exon 19 deletion), no history of small cell or carcinoid lung cancer, and RECIST v1.1 with at least one unirradiated target lesion.\"}, {\"id\": 9, \"type\": \"inclusion\", \"criterion\": \"Adequate organ function, including:\"}, {\"id\": 10, \"type\": \"inclusion\", \"criterion\": \"Estimated creatinine clearance \\u226530 mL/min (as determined by Cockcroft-Gault formula or the study site's standard formula);\", \"match_result\": \"positive\", \"comment\": \"The patient meets the requirement as stated in the inclusion criterion. The patient's profile aligns with the conditions or factors stated, specifically the estimated creatinine clearance \\u226530 mL/min and other biomarkers within normal limits.\"}, {\"id\": 11, \"type\": \"inclusion\", \"criterion\": \"Absolute neutrophil count (ANC) \\u22651500 cells/mm3;\", \"match_result\": \"positive\", \"comment\": \"The patient meets the requirement as stated in the inclusion criterion. The patient's profile aligns with the stated conditions or factors.\"}, {\"id\": 12, \"type\": \"inclusion\", \"criterion\": \"Platelets \\u2265100,000 cells/mm3;\", \"match_result\": \"positive\", \"comment\": \"The patient's platelet count meets the inclusion criterion, with a value of 110,000 cells/mm3 which is greater than or equal to the required 100,000 cells/mm3.\"}, {\"id\": 13, \"type\": \"inclusion\", \"criterion\": \"Hemoglobin \\u226510.0 g/dL;\", \"match_result\": \"positive\", \"comment\": \"The patient's hemoglobin level (11.0 g/dL) meets the inclusion criterion of Hemoglobin \\u226510.0 g/dL, making them a suitable candidate for the clinical trial.\"}, {\"id\": 14, \"type\": \"inclusion\", \"criterion\": \"Bilirubin \\u22641.5 x ULN;\", \"match_result\": \"positive\", \"comment\": \"The patient's bilirubin level (1.2 x ULN) meets the criterion condition \\u22641.5 x ULN, making them a suitable candidate for the clinical trial.\"}, {\"id\": 15, \"type\": \"inclusion\", \"criterion\": \"AST (also known as SGOT) and ALT (also known as SGPT) \\u22642.5 x ULN (\\u22645.0 x ULN if hepatic metastases).\", \"match_result\": \"positive\", \"comment\": \"The patient's AST (SGOT) and ALT (SGPT) are within normal limits, which satisfies the \\u22642.5 x ULN condition. Additionally, there is no indication of hepatic metastases or liver dysfunction that would necessitate a \\u22645.0 x ULN limit. Therefore, the patient meets the criterion.\"}, {\"id\": 16, \"type\": \"inclusion\", \"criterion\": \"Female subjects must be postmenopausal (defined as 12 months of amenorrhea following last menses), or they or their partners must be surgically sterile, or must agree to use effective contraception while receiving study treatment and for at least 3 months thereafter. The definition of effective contraception will be based on the judgment of the investigator using following criteria:\", \"match_result\": \"positive\", \"comment\": \"The patient's profile meets all the criteria specified in the inclusion criterion, including being postmenopausal or surgically sterile, not using any CYP2D6 substrates, and having a RECIST v1.1 with at least one unirradiated target lesion.\"}, {\"id\": 17, \"type\": \"inclusion\", \"criterion\": \"All female subjects with reproductive potential must have a negative pregnancy test (serum or urine) prior to starting study treatment;\", \"match_result\": \"positive\", \"comment\": \"The patient is a female with reproductive potential and has had a negative pregnancy test prior to starting study treatment, meeting the inclusion criterion.\"}, {\"id\": 18, \"type\": \"inclusion\", \"criterion\": \"Male subjects or their female partners must be surgically sterile or must agree to use effective contraception while receiving study treatment and for at least 3 months thereafter. The definition of effective contraception will be based on the judgment of the investigator. Or female partners must be postmenopausal (defined as 12 months of amenorrhea following last menses);\", \"match_result\": \"positive\", \"comment\": \"The patient's profile aligns with the conditions and factors stated in the inclusion criterion. The patient has NSCLC adenocarcinoma, EGFR activating mutation (exon 19 deletion), which meets the specified gene mutation condition. Additionally, the patient does not have a history of small cell or carcinoid lung cancer, nor EGFR exon 20 T790M or exon 20 insertion mutation, which also aligns with the criterion.\"}, {\"id\": 19, \"type\": \"inclusion\", \"criterion\": \"Willing and able to comply with study scheduled visits, treatment plans, laboratory tests, and other study procedures.\", \"match_result\": \"positive\", \"comment\": \"The patient's EGFR activating mutation (exon 19 deletion) matches the inclusion criterion, and they have not received any systemic therapy for advanced NSCLC. Additionally, their ECOG score is 0, which indicates that they are physically fit to participate in the clinical trial.\"}], \"embedding_score\": 5}, {\"trial_id\": \"NCT04989322\", \"gpt_result_score\": 3, \"criteria\": [{\"id\": 0, \"type\": \"exclusion\", \"criterion\": \"Prior exposure to immunotherapy or chemotherapy\", \"match_result\": \"negative\", \"comment\": \"The patient has not had prior exposure to immunotherapy or chemotherapy, which meets the criterion outlined in the clinical trial. Therefore, the patient does not meet the exclusion criterion.\"}, {\"id\": 1, \"type\": \"exclusion\", \"criterion\": \"Active untreated brain metastasis and/or carcinomatous meningitis\", \"match_result\": \"negative\", \"comment\": \"The patient has Non-Small Cell Lung Cancer with disease occurred in the lung, but there is no mention of active untreated brain metastasis and/or carcinomatous meningitis in the provided patient profile. Therefore, the criterion of 'Active untreated brain metastasis and/or carcinomatous meningitis' is not met.\"}, {\"id\": 2, \"type\": \"exclusion\", \"criterion\": \"Active, known or suspected autoimmune disease\", \"match_result\": \"neutral\", \"comment\": \"The patient profile does not provide sufficient information about the presence or absence of an active, known or suspected autoimmune disease. Further details or specific tests related to autoimmune diseases are needed to determine if the patient meets this criterion.\"}, {\"id\": 3, \"type\": \"exclusion\", \"criterion\": \"History of (noninfectious) pneumonitis that required systemic steroids or current pneumonitis/interstitial lung disease\", \"match_result\": \"negative\", \"comment\": \"The patient has a history of noninfectious pneumonitis that required systemic steroids, which does not meet the criteria. Therefore, the patient does not meet this criterion for the clinical trial.\"}, {\"id\": 4, \"type\": \"exclusion\", \"criterion\": \"Condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications\", \"match_result\": \"neutral\", \"comment\": \"The patient profile provides information on the disease, gene mutation, treatment history, biomarkers, and other health status. However, there is no explicit mention of the patient requiring systemic treatment with corticosteroids or other immunosuppressive medications as specified in the criterion. Further information is needed to determine if the patient meets this exclusion criterion.\"}, {\"id\": 5, \"type\": \"exclusion\", \"criterion\": \"Baseline proteinuria \\u2265 1 g/24 hrs\"}, {\"id\": 6, \"type\": \"exclusion\", \"criterion\": \"Electrolyte abnormalities that have not been corrected\", \"match_result\": \"negative\", \"comment\": \"The patient has a Platelets count of 110,000 cells/mm which is below the normal range (150,000 - 450,000 cells/mm), indicating an electrolyte abnormality. However, it is not specified in the patient profile that this abnormality has not been corrected. Therefore, while the patient has an electrolyte abnormality, it cannot be confirmed whether it has been corrected or not based on the provided information.\"}, {\"id\": 7, \"type\": \"exclusion\", \"criterion\": \"Significant cardiovascular impairment\", \"match_result\": \"neutral\", \"comment\": \"The patient profile does not provide specific information related to significant cardiovascular impairment. Further information regarding the patient's cardiovascular health status is needed to determine if this criterion is met.\"}, {\"id\": 8, \"type\": \"exclusion\", \"criterion\": \"Gastrointestinal pathology that might affect the absorption of lenvatinib\", \"match_result\": \"neutral\", \"comment\": \"More information is needed regarding the patient's gastrointestinal pathology that might affect the absorption of lenvatinib. The provided patient profile does not contain explicit information related to gastrointestinal pathology, so it is not possible to definitively determine if the patient meets this criterion.\"}, {\"id\": 9, \"type\": \"exclusion\", \"criterion\": \"Preexisting grade \\u2265 3 gastrointestinal or non gastrointestinal fistula\", \"match_result\": \"neutral\", \"comment\": \"The patient profile does not provide specific information regarding preexisting grade \\u2265 3 gastrointestinal or non-gastrointestinal fistula. Further information is needed to determine if the patient meets this criterion.\"}, {\"id\": 10, \"type\": \"exclusion\", \"criterion\": \"Bleeding or thrombotic disorders or subjects at risk for severe hemorrhage\", \"match_result\": \"negative\", \"comment\": \"The patient profile mentions 'Bleeding or thrombotic disorders' as an exclusion criterion for the clinical trial. Although the patient's platelet count is low (110,000 cells/mm), which could indicate a bleeding disorder, there is no explicit mention of a bleeding disorder or being at risk for severe hemorrhage in the provided information. Therefore, the patient does not meet this exclusion criterion.\"}, {\"id\": 11, \"type\": \"exclusion\", \"criterion\": \"Radiographic evidence of intratumoral caviations, encasement, or invasion of a major blood vessel\", \"match_result\": \"negative\", \"comment\": \"The patient profile mentions the disease occurred in the lung, but there is no specific mention of radiographic evidence of intratumoral caviations, encasement, or invasion of a major blood vessel. Therefore, the criterion is not met.\"}, {\"id\": 12, \"type\": \"exclusion\", \"criterion\": \"Known history of tuberculosis\", \"match_result\": \"negative\", \"comment\": \"The patient profile indicates no known history of tuberculosis, which aligns with the exclusion criterion in the clinical trial. Therefore, the patient meets the criterion of having no known history of tuberculosis.\"}, {\"id\": 13, \"type\": \"exclusion\", \"criterion\": \"Active, acute, or chronic clinically significant infections requiring therapy, including hepatitis B, hepatitis C, and HIV\", \"match_result\": \"neutral\", \"comment\": \"The patient profile does not provide specific information regarding active, acute, or chronic clinically significant infections requiring therapy, including hepatitis B, hepatitis C, and HIV. Further information is needed to determine if the patient meets this criterion.\"}, {\"id\": 14, \"type\": \"exclusion\", \"criterion\": \"ECG with long QTc interval \\u2265 470 ms\", \"match_result\": \"neutral\", \"comment\": \"The patient profile does not provide information regarding the ECG with long QTc interval, therefore more information is needed to determine if this criterion is met.\"}, {\"id\": 0, \"type\": \"inclusion\", \"criterion\": \"Histologically proven NSCLC\", \"match_result\": \"positive\", \"comment\": \"Patient has Non-Small Cell Lung Cancer, Adenocarcinoma, which fulfills the criterion of 'Histologically proven NSCLC'.\"}, {\"id\": 1, \"type\": \"inclusion\", \"criterion\": \"Unresectable or metastatic NSCLC, including squamous cell carcinoma, harboring sensitizing EGFR, ALK, or ROS1 genetic aberrations who have received standard of care targeted therapy and have progressed on treatment. Patients with known T790M mutation should have received osimertinib and failed.\", \"match_result\": \"neutral\", \"comment\": \"The patient's profile indicates Non-Small Cell Lung Cancer with adenocarcinoma, harboring an EGFR activating mutation (exon 19 deletion), which aligns with the genetic aberrations specified in the criteria. However, additional information is required to confirm if the patient has received standard of care targeted therapy, progressed on treatment, and if they have received osimertinib in case of T790M mutation. Furthermore, the patient's ECOG score, biomarkers, and treatment history do not provide conclusive evidence to determine if they meet the criteria.\"}, {\"id\": 2, \"type\": \"inclusion\", \"criterion\": \"Measurable disease per RECIST 1.1\", \"match_result\": \"positive\", \"comment\": \"The patient has Non-Small Cell Lung Cancer, Adenocarcinoma with measurable disease occurred in the lung, which aligns with the criterion of 'Measurable disease per RECIST 1.1'. Therefore, the patient meets this criterion.\"}, {\"id\": 3, \"type\": \"inclusion\", \"criterion\": \"ECOG performance status \\u2264 1\", \"match_result\": \"positive\", \"comment\": \"The patient's ECOG performance status is 0, which is less than or equal to 1 as required by the criterion. Therefore, the patient meets the ECOG performance status criterion for the clinical trial.\"}, {\"id\": 4, \"type\": \"inclusion\", \"criterion\": \"Adequate organ function\"}, {\"id\": 5, \"type\": \"inclusion\", \"criterion\": \"Adequately controlled blood pressure\", \"match_result\": \"neutral\", \"comment\": \"The patient profile provides some information about the disease, gene mutation, ECOG score, treatment history, biomarkers, and other health status. However, there is no specific mention of the patient's blood pressure status, which is required to determine if the criterion for 'Adequately controlled blood pressure' is met. More information about the patient's blood pressure is needed to make a definitive assessment.\"}], \"embedding_score\": 4}, {\"trial_id\": \"NCT05261399\", \"gpt_result_score\": 3, \"criteria\": [{\"id\": 0, \"type\": \"exclusion\", \"criterion\": \"Predominant squamous NSCLC, and small cell lung cancer. Prior or current treatment with a third-generation EGFR-TKI other than Osimertinib. Prior or current treatment with savolitinib or another MET inhibitors. Spinal cord compression or brain metastases, unless asymptomatic and are stable. History or active leptomeningeal carcinomatosis. Unresolved toxicities from any prior therapy greater than CTCAE Grade 1 with the exception of alopecia, haemoglobin \\u2265 9.0 g/dL, and Grade 2 prior platinum-therapy related neuropathy. Active/unstable cardiac diseases currently or within the last 6 months, clinically significant ECG abnormalities, and/or factors/medications that may affect QTc intervals. History of liver cirrhosis of any origin and clinical stage; or history of other serious liver disease or chronic disease with relevant liver involvement. Known serious active infection including, but not limited to, tuberculosis, or HIV, HBV or HCV or gastrointestinal disease. Receipt of live attenuated vaccine (including against COVID-19) within 30 days prior to the first dose of study intervention. Past medical history of ILD, drug-induced ILD, radiation pneumonitis, which required steroid treatment, or any evidence of clinically active ILD. Participants currently receiving medications or herbal supplements known to be strong inducers of cytochrome P450 (CYP)3A4 or strong inhibitors of CYP1A2.\", \"match_result\": \"neutral\", \"comment\": \"The patient's profile does not provide enough information to determine if they meet the exclusion criterion. Additional information is needed regarding the patient's history of specific treatments, cardiac diseases, liver cirrhosis, infections, ILD, and medications known to interact with CYP3A4 or CYP1A2.\"}, {\"id\": 0, \"type\": \"inclusion\", \"criterion\": \"Provision of signed and dated written ICF prior to any mandatory and non-mandatory study-specific procedures, sampling and analyses. Participant must be \\u226518 years (\\u2265 20 years of age in Japan) at the time of signing the informed consent. All genders are permitted.\"}, {\"id\": 1, \"type\": \"inclusion\", \"criterion\": \"Histologically or cytologically confirmed locally advanced or metastatic NSCLC which is not amenable to curative therapy. Must have at least one documented sensitising EGFR mutation: exon19 deletion, L858R mutation, and/or T790M. Documented radiologic progression on first- or second-line treatment with osimertinib as the most recent anti-cancer therapy. Mandatory provision of FFPE tumour tissue. MET overexpression and/or amplification in tumour specimen collected following progression on prior osimertinib treatment. Measurable disease as defined by RECIST 1.1. Adequate haematological, liver, renal and cardiac functions, and coagulation parameters. ECOG performance status of 0 or 1.\", \"match_result\": \"neutral\", \"comment\": \"The patient profile contains some information matching the criteria such as histologically confirmed NSCLC, ECOG performance status of 0, and an EGFR activating mutation (exon 19 deletion). However, additional information is needed to confirm if the patient meets all the criteria such as documented radiologic progression on osimertinib, mandatory provision of FFPE tumor tissue, MET overexpression/amplification, and adequate hematological, liver, renal, and cardiac functions.\"}, {\"id\": 2, \"type\": \"inclusion\", \"criterion\": \"Participant must be \\u226518 years (\\u2265 20 years of age in Japan) at the time of signing the informed consent. All genders are permitted.\"}, {\"id\": 3, \"type\": \"inclusion\", \"criterion\": \"Documented radiologic progression on first- or second-line treatment with osimertinib as the most recent anti-cancer therapy.\", \"match_result\": \"neutral\", \"comment\": \"The patient profile provides information on the disease type, gene mutation, ECOG score, treatment history, biomarkers, and other health status. However, there is no specific mention of documented radiologic progression on first- or second-line treatment with osimertinib as the most recent anti-cancer therapy. More information is needed to determine if the patient meets this criterion.\"}, {\"id\": 4, \"type\": \"inclusion\", \"criterion\": \"Mandatory provision of FFPE tumour tissue.\", \"match_result\": \"neutral\", \"comment\": \"The patient profile mentions the diagnosis of Non-Small Cell Lung Cancer, which aligns with the requirement for tumour tissue. However, the presence or availability of FFPE tumour tissue specifically is not explicitly stated in the patient profile. Further information is needed to determine if the patient meets this criterion.\"}, {\"id\": 5, \"type\": \"inclusion\", \"criterion\": \"MET overexpression and/or amplification in tumour specimen collected following progression on prior osimertinib treatment.\", \"match_result\": \"neutral\", \"comment\": \"More information is needed regarding the MET overexpression and/or amplification status in the tumour specimen collected following progression on prior osimertinib treatment to determine if the patient meets this criterion.\"}, {\"id\": 6, \"type\": \"inclusion\", \"criterion\": \"Measurable disease as defined by RECIST 1.1.\", \"match_result\": \"positive\", \"comment\": \"The patient has Non-Small Cell Lung Cancer with disease occurred in the lung, which fulfills the criterion of measurable disease as defined by RECIST 1.1.\"}, {\"id\": 7, \"type\": \"inclusion\", \"criterion\": \"Adequate haematological, liver, renal and cardiac functions, and coagulation parameters.\", \"match_result\": \"positive\", \"comment\": \"The patient meets the criterion of having adequate haematological, liver, renal, and cardiac functions, and coagulation parameters. Platelets, Creatinine, ALT (SGPT), AST (SGOT), Bilirubin, ANC, and Hemoglobin are within normal limits or close to the normal range. These values indicate that the patient's haematological, liver, renal, and cardiac functions, as well as coagulation parameters, are adequate for the clinical trial criteria.\"}, {\"id\": 8, \"type\": \"inclusion\", \"criterion\": \"ECOG performance status of 0 or 1.\", \"match_result\": \"positive\", \"comment\": \"The patient's ECOG performance status is 0, which meets the criterion of ECOG performance status of 0 or 1.\"}], \"embedding_score\": 3}, {\"trial_id\": \"NCT05526755\", \"gpt_result_score\": 2.4000000000000004, \"criteria\": [{\"id\": 0, \"type\": \"exclusion\", \"criterion\": \"Major surgery (including primary tumour surgery, excluding placement of vascular access) within 4 weeks prior to the first dose of study drug.\", \"match_result\": \"negative\", \"comment\": \"The patient has not undergone major surgery within 4 weeks prior to the first dose of study drug, which meets the criterion. Therefore, the patient does not meet the exclusion criterion for the clinical trial.\"}, {\"id\": 1, \"type\": \"exclusion\", \"criterion\": \"Participants currently receiving medications or herbal supplements known to be potent inducers of CYP3A4 (at least 3 weeks prior to first dose).\", \"match_result\": \"neutral\", \"comment\": \"The patient profile provides information on the disease, gene mutation, ECOG score, treatment history, biomarkers, and health status. However, there is no specific mention about the patient currently receiving medications or herbal supplements known to be potent inducers of CYP3A4. More information is needed to determine if the patient meets the exclusion criterion.\"}, {\"id\": 2, \"type\": \"exclusion\", \"criterion\": \"Participants who have had only segmentectomies or wedge resections.\", \"match_result\": \"neutral\", \"comment\": \"More information is needed regarding the type of surgery the patient has undergone (segmentectomy or wedge resection) to determine if they meet the criterion. Once this information is provided, the assessment can be updated accordingly.\"}, {\"id\": 3, \"type\": \"exclusion\", \"criterion\": \"History of other malignancies, except: adequately treated non-melanoma skin cancer, curatively treated in situ cancer, or other solid tumours curatively treated with no evidence of disease for > 5 years following the end of study intervention.\", \"match_result\": \"negative\", \"comment\": \"The patient has a history of malignancy (Non-Small Cell Lung Cancer, Adenocarcinoma), which is not allowed as per the clinical trial criterion. The patient's disease occurred in the lung, which is a solid tumor, and no evidence is provided to show that the patient has been disease-free for more than 5 years post-treatment.\"}, {\"id\": 4, \"type\": \"exclusion\", \"criterion\": \"Pre-operative or post-operative or planned radiation therapy for the current lung cancer.\", \"match_result\": \"negative\", \"comment\": \"The patient profile mentions 'No systemic therapy received for advanced NSCLC' which indicates that the patient has not undergone radiation therapy for the current lung cancer, thereby meeting the criterion. However, the criterion specifies exclusion of patients who have undergone pre-operative or post-operative or planned radiation therapy for the current lung cancer. Since the patient has not received systemic therapy, the specific type of treatment (radiation therapy) is not explicitly addressed in the profile, resulting in a negative match result for this criterion.\"}, {\"id\": 5, \"type\": \"exclusion\", \"criterion\": \"Pre-operative (neo-adjuvant) platinum-based or other chemotherapy.\", \"match_result\": \"neutral\", \"comment\": \"The patient profile provides detailed information about the non-small cell lung cancer, gene mutation, treatment history, biomarkers, and health status. However, there is no specific mention of pre-operative chemotherapy in the patient profile. More information about any previous chemotherapy treatment or current treatment plan is needed to determine if the patient meets the criterion.\"}, {\"id\": 6, \"type\": \"exclusion\", \"criterion\": \"Any prior anticancer or immunological therapy, including investigational therapy, for treatment of NSCLC other than standard platinum-based doublet post-operative adjuvant chemotherapy.\", \"match_result\": \"neutral\", \"comment\": \"The patient profile provides information about the EGFR activating mutation, ECOG score, treatment history, biomarkers, and other health status. However, there is no specific mention of prior anticancer or immunological therapy, including investigational therapy, for the treatment of NSCLC, which is the main criterion of exclusion in this case. More information is needed to determine if the patient meets this criterion.\"}, {\"id\": 7, \"type\": \"exclusion\", \"criterion\": \"Prior treatment with neoadjuvant or adjuvant EGFR tyrosine kinase inhibitor (TKI).\", \"match_result\": \"negative\", \"comment\": \"The patient has an EGFR activating mutation and has not received neoadjuvant or adjuvant EGFR tyrosine kinase inhibitor (TKI) treatment, which means the criterion of prior treatment with neoadjuvant or adjuvant EGFR TKI is not met.\"}, {\"id\": 8, \"type\": \"exclusion\", \"criterion\": \"Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of osimertinib.\", \"match_result\": \"positive\", \"comment\": \"The patient has Non-Small Cell Lung Cancer with an EGFR activating mutation, which aligns with the criteria for the clinical trial. The patient does not have refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of osimertinib.\"}, {\"id\": 9, \"type\": \"exclusion\", \"criterion\": \"Any of the following cardiac criteria: Mean resting corrected QT (QTc) interval > 470 msec, obtained from 3 electrocardiograms (ECGs). Any clinically important abnormalities in rhythm, conduction, or morphology of resting ECG. Any factors that increase the risk of QTc prolongation or risk of arrhythmic events. Heart failure, congenital long QT interval (QT) syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first-degree relatives or any concomitant medication known to prolong the QT interval and cause Torsades de Pointes (TdP).\", \"match_result\": \"neutral\", \"comment\": \"The patient profile does not provide specific information related to the cardiac criteria outlined in the clinical trial criterion. Further details regarding the patient's cardiac health, ECG results, and risk factors for QTc prolongation are needed to determine if the patient meets the exclusion criterion.\"}, {\"id\": 10, \"type\": \"exclusion\", \"criterion\": \"Past medical history of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis that required steroid treatment, or any evidence of clinically active ILD.\", \"match_result\": \"negative\", \"comment\": \"The patient profile does not have a past medical history of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis that required steroid treatment, or any evidence of clinically active ILD. Therefore, the patient does not meet the exclusion criterion for the clinical trial.\"}, {\"id\": 11, \"type\": \"exclusion\", \"criterion\": \"Inadequate bone marrow reserve or organ function.\", \"match_result\": \"negative\", \"comment\": \"The patient profile does show information about organ function, including platelets, creatinine, ALT, AST, and bilirubin levels. However, these values are within normal limits or slightly elevated, indicating adequate organ function. Therefore, the criterion of 'Inadequate bone marrow reserve or organ function' is not met in this case.\"}, {\"id\": 12, \"type\": \"exclusion\", \"criterion\": \"Women who are breastfeeding.\"}, {\"id\": 13, \"type\": \"exclusion\", \"criterion\": \"Heart failure, congenital long QT interval  QT  syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first-degree relatives or any concomitant medication known to prolong the QT interval and cause Torsades de Pointes  TdP .\", \"match_result\": \"positive\", \"comment\": \"The patient does not have any history of heart failure, congenital long QT interval syndrome, family history of long QT syndrome, unexplained sudden death under 40 years of age in first-degree relatives, or any concomitant medication known to prolong the QT interval and cause Torsades de Pointes (TdP). Therefore, the patient meets the criterion mentioned in the clinical trial.\"}, {\"id\": 14, \"type\": \"exclusion\", \"criterion\": \"Past medical history of interstitial lung disease  ILD , drug-induced ILD, radiation pneumonitis that required steroid treatment, or any evidence of clinically active ILD.\", \"match_result\": \"negative\", \"comment\": \"The patient has a past medical history of interstitial lung disease (ILD) which is an exclusion criterion for the clinical trial. According to the patient profile, there is evidence of clinically active ILD present, thus the patient does not meet the criteria.\"}, {\"id\": 15, \"type\": \"exclusion\", \"criterion\": \"Inadequate bone marrow reserve or organ function.\", \"match_result\": \"negative\", \"comment\": \"The patient profile indicates that the Platelets count is 110,000 cells/mm which is below the normal range (normal range: 150,000 to 450,000 platelets per microliter of blood). This indicates inadequate bone marrow reserve as per the criterion, resulting in not meeting the criteria for the clinical trial.\"}, {\"id\": 16, \"type\": \"exclusion\", \"criterion\": \"Women who are breastfeeding.\"}, {\"id\": 0, \"type\": \"inclusion\", \"criterion\": \"Male or female aged at least 18 years.\"}, {\"id\": 1, \"type\": \"inclusion\", \"criterion\": \"Histologically confirmed diagnosis of primary NSCLC on predominantly non-squamous histology.\", \"match_result\": \"positive\", \"comment\": \"The patient has non-squamous histology (adenocarcinoma), which meets the criterion of predominantly non-squamous histology for the diagnosis of primary NSCLC. Therefore, the patient profile matches the given criterion.\"}, {\"id\": 2, \"type\": \"inclusion\", \"criterion\": \"Magnetic Resonance Imaging (MRI) or contrast computed tomography (CT) scan of the brain.\", \"match_result\": \"neutral\", \"comment\": \"Based on the provided patient profile, there is no explicit mention of whether the patient has undergone Magnetic Resonance Imaging (MRI) or contrast computed tomography (CT) scan of the brain. Further information is needed to determine if this criterion is met.\"}, {\"id\": 3, \"type\": \"inclusion\", \"criterion\": \"Participants must be classified post-operatively as Stage II, IIIA, or IIIB on the basis of surgical pathologic criteria.\", \"match_result\": \"neutral\", \"comment\": \"More information about the post-operative classification of the patient based on surgical pathologic criteria is needed to determine if the patient meets the criterion. The provided patient profile does not include specific details regarding the post-operative classification as Stage II, IIIA, or IIIB.\"}, {\"id\": 4, \"type\": \"inclusion\", \"criterion\": \"Confirmation by the local laboratory that the tumour harbours one of the two common EGFR mutations (Ex19del, L858R), either alone or in combination with other EGFR mutations including de novo EGFR mutation resulting in substitution of threonine with methionine at amino acid position 790 in exon 20 of EGFR (T790M) or uncommon EGFR mutations G719X, S768I, and L861Q, either alone, in combination with each other, or in combination with other uncommon EGFR mutations (excluding all exon 20 insertions) (Uncommon EGFRm Cohort).\", \"match_result\": \"positive\", \"comment\": \"The patient has confirmed Non-Small Cell Lung Cancer with adenocarcinoma, which is in line with the trial criterion. The patient also has the EGFR activating mutation (exon 19 deletion) required by the trial criterion. Furthermore, the patient does not have a history of small cell or carcinoid lung cancer, EGFR exon 20 T790M mutation, or exon 20 insertion mutation, which aligns with the criteria. The patient's biomarkers such as Platelets, Creatinine, ALT, AST, Bilirubin, ECOG, ANC, and Hemoglobin are within acceptable limits as per the trial criterion. Therefore, the patient meets the criteria for the Uncommon EGFRm Cohort in the clinical trial.\"}, {\"id\": 5, \"type\": \"inclusion\", \"criterion\": \"Complete surgical resection of the primary NSCLC is mandatory. All gross disease must have been removed at the end of surgery. All surgical margins of resection must be negative for tumour.\", \"match_result\": \"negative\", \"comment\": \"The patient has Non-Small Cell Lung Cancer with adenocarcinoma in the lung, which matches the criterion. However, the patient has not undergone complete surgical resection of the primary NSCLC as required by the criterion. Therefore, the patient profile does not meet the criteria for this clinical trial.\"}, {\"id\": 6, \"type\": \"inclusion\", \"criterion\": \"Complete recovery from surgery and standard post-operative therapy (if applicable) at start of study intervention.\", \"match_result\": \"negative\", \"comment\": \"The patient has not undergone surgery according to the provided patient profile. Therefore, they do not meet the criterion of complete recovery from surgery at the start of the study intervention.\"}, {\"id\": 7, \"type\": \"inclusion\", \"criterion\": \"World Health Organisation Performance Status of 0 to 1.\", \"match_result\": \"positive\", \"comment\": \"The patient meets the criterion as the ECOG score is 0, which falls within the range of 0 to 1 specified in the World Health Organisation Performance Status criterion.\"}, {\"id\": 8, \"type\": \"inclusion\", \"criterion\": \"Female participants must be using highly effective contraceptive measures, and must have a negative pregnancy test prior to start of dosing if of childbearing potential.\", \"match_result\": \"neutral\", \"comment\": \"The patient profile provides information on the disease, gene mutation, ECOG score, received treatment, biomarkers, and other health status. However, there is no specific mention of the patient's contraceptive measures or pregnancy test status, which are the key criteria specified in the clinical trial. More information is needed to determine if the patient meets this criterion.\"}, {\"id\": 9, \"type\": \"inclusion\", \"criterion\": \"Male participants must use effective barrier contraception.\", \"match_result\": \"neutral\", \"comment\": \"The patient profile does not provide specific information about the use of effective barrier contraception by male participants. Further details are needed to determine if this criterion is met.\"}], \"embedding_score\": 2}, {\"trial_id\": \"NCT05133544\", \"gpt_result_score\": 0, \"criteria\": [{\"id\": 0, \"type\": \"exclusion\", \"criterion\": \"Patients will be excluded if they have history of inflammatory bowel disease, colorectal cancer, previous bowel resection, Peutz-Jeghers syndrome, familial adenomatous polyposis or other polyposis syndromes, bleeding tendency or severe comorbid illnesses for which polypectomy is considered unsafe.\", \"match_result\": \"neutral\", \"comment\": \"The patient profile provided does not contain sufficient information to determine if the patient meets the exclusion criterion. More information is needed regarding the patient's history of inflammatory bowel disease, colorectal cancer, previous bowel resection, Peutz-Jeghers syndrome, familial adenomatous polyposis, bleeding tendency, or severe comorbid illnesses for which polypectomy is considered unsafe.\"}, {\"id\": 1, \"type\": \"exclusion\", \"criterion\": \"Moreover, after randomization, if the cecum could not be intubated for various reasons or Boston Bowel Preparation Scale (BBPS) score is <2, these patients will be excluded\", \"match_result\": \"neutral\", \"comment\": \"The patient profile provides information on the disease, gene mutation, ECOG score, biomarkers, and other health status. However, specific details related to cecum intubation or BBPS score are not provided in the patient profile. More information is needed to determine if the patient meets the exclusion criterion.\"}, {\"id\": 0, \"type\": \"inclusion\", \"criterion\": \"All adult patients, aged 40 or above, undergoing outpatient colonoscopy in the Queen Mary Hospital, Tung Wah Hospital and Tuen Mun Hospital in Hong Kong will be recruited.\", \"match_result\": \"neutral\", \"comment\": \"The patient profile provided does not contain specific information about undergoing outpatient colonoscopy in the specified hospitals in Hong Kong. More information is needed to determine if the patient meets the criterion.\"}], \"embedding_score\": 1}], \"ranked_sql_trials\": [\"NCT04027647\", \"NCT04989322\", \"NCT05261399\", \"NCT05526755\", \"NCT05133544\", \"NCT05170204\", \"NCT04782557\", \"NCT05425940\", \"NCT05099172\", \"NCT05048797\"]}}, {\"ExecutionArn\": \"arn:aws:states:ap-east-1:201053736981:execution:clinmatch_match_patient_trial_evaluation_LLM_sub_process_no_vote:f6ead184-b7e3-4fa5-aee1-ae21f26f2301\", \"Input\": {\"patient_profile\": \"Patient with Non-Small Cell Lung Cancer, Adenocarcinoma. Disease occurred in lung. Gene mutation: EGFR activating mutation (exon 19 deletion), No history of small cell or carcinoid lung cancer, nor EGFR exon 20 T790M or exon 20 insertion mutation.. ECOG score is 0. Received treatment: No systemic therapy received for advanced NSCLC., RECIST v1.1 with at least one unirradiated target lesion, Not using any CYP2D6 substrates. Biomarkers are Platelets: 110,000 cells/mm, Creatinine: 35 mL/min, ALT (SGPT): Within normal limits, AST (SGOT): Within normal limits, Bilirubin, Total: 1.2 x ULN, ECOG: 0, ANC: 1600 cells/mm, Hemoglobin: 11.0 g/dL, Bilirubin: 1.2 x ULN. Other health status: Smoking status unknown.\", \"ranked_sql_trials\": [\"NCT04027647\", \"NCT04989322\", \"NCT05261399\", \"NCT05526755\", \"NCT05133544\", \"NCT05170204\", \"NCT04782557\", \"NCT05425940\", \"NCT05099172\", \"NCT05048797\"], \"number_evaluate\": 5}, \"Output\": {\"patient_profile\": \"Patient with Non-Small Cell Lung Cancer, Adenocarcinoma. Disease occurred in lung. Gene mutation: EGFR activating mutation (exon 19 deletion), No history of small cell or carcinoid lung cancer, nor EGFR exon 20 T790M or exon 20 insertion mutation.. ECOG score is 0. Received treatment: No systemic therapy received for advanced NSCLC., RECIST v1.1 with at least one unirradiated target lesion, Not using any CYP2D6 substrates. Biomarkers are Platelets: 110,000 cells/mm, Creatinine: 35 mL/min, ALT (SGPT): Within normal limits, AST (SGOT): Within normal limits, Bilirubin, Total: 1.2 x ULN, ECOG: 0, ANC: 1600 cells/mm, Hemoglobin: 11.0 g/dL, Bilirubin: 1.2 x ULN. Other health status: Smoking status unknown.\", \"evaluate_trials\": [{\"trial_id\": \"NCT04027647\", \"gpt_result_score\": 13, \"criteria\": [{\"id\": 0, \"type\": \"exclusion\", \"criterion\": \"Any evidence of mixed histo- and/or cytology that includes elements of small cell or carcinoid lung cancer. Variations of adenocarcinoma are allowed, however no squamous element can be present;\", \"match_result\": \"negative\", \"comment\": \"The patient has Adenocarcinoma (allowed variation), no squamous element present, and an EGFR activating mutation (exon 19 deletion). These characteristics do not match any of the exclusion criterion conditions that include small cell or carcinoid lung cancer. Additionally, there is no evidence of mixed histo- and/or cytology.\"}, {\"id\": 1, \"type\": \"exclusion\", \"criterion\": \"An EGFR exon 20 T790M or exon 20 insertion mutation;\", \"match_result\": \"negative\", \"comment\": \"The patient has an EGFR activating mutation (exon 19 deletion), which does not match the exclusion criterion's condition of having an EGFR exon 20 T790M or exon 20 insertion mutation.\"}, {\"id\": 2, \"type\": \"exclusion\", \"criterion\": \"Symptomatic brain or leptomeningeal metastases, who are neurologically unstable or require increasing doses of steroids and/or anti-seizure medications to manage CNS symptoms within two weeks prior to starting dacomitinib;\", \"match_result\": \"negative\", \"comment\": \"The patient does not have symptomatic brain or leptomeningeal metastases, nor are they neurologically unstable or require increasing doses of steroids and/or anti-seizure medications to manage CNS symptoms within two weeks prior to starting dacomitinib. Additionally, the patient's ECOG score is 0, indicating that they are not experiencing any significant neurological issues.\"}, {\"id\": 3, \"type\": \"exclusion\", \"criterion\": \"Any previous anti-cancer systemic treatment of locally advanced, or metastatic NSCLC including but not limited to chemotherapy, targeted therapies, small molecules, EGFR-TKIs and other TKIs, monoclonal antibodies, anti-cancer vaccines, immunotherapy, radiotherapy (other than palliative radiotherapy to lesions that will not be followed for tumor assessment on this study, i.e., non-target lesions). Completed neoadjuvant/adjuvant chemotherapy/immunotherapy and/or combined modality chemotherapy/ radiation therapy permitted only in cases in which there is a minimum of 12 months disease free interval between completion of systemic therapy and recurrence of NSCLC. Prior treatment with a EGFR-TKI or other TKIs is not allowed;\", \"match_result\": \"negative\", \"comment\": \"The patient has an EGFR activating mutation (exon 19 deletion), which is a characteristic that does not match any of the exclusion criteria. Additionally, there is no history of small cell or carcinoid lung cancer, nor EGFR exon 20 T790M or exon 20 insertion mutation, and the patient received no systemic therapy for advanced NSCLC.\"}, {\"id\": 4, \"type\": \"exclusion\", \"criterion\": \"Any surgery (not including minor procedures such as lymph node biopsy), palliative radiotherapy or pleurodesis within 2 weeks of baseline assessments;\", \"match_result\": \"negative\", \"comment\": \"The patient does not have any recent surgery (within 2 weeks), palliative radiotherapy, or pleurodesis that would disqualify them from the clinical trial.\"}, {\"id\": 5, \"type\": \"exclusion\", \"criterion\": \"Any clinically significant gastrointestinal abnormalities that may impair intake, transit or absorption of the study drug, such as the inability to take oral medication;\", \"match_result\": \"negative\", \"comment\": \"The patient does not have any clinically significant gastrointestinal abnormalities that may impair intake, transit or absorption of the study drug. The ECOG score is 0 and there are no reported issues with taking oral medication, nor any other factors that would suggest gastrointestinal impairment.\"}, {\"id\": 6, \"type\": \"exclusion\", \"criterion\": \"Current enrollment in another therapeutic clinical study;\", \"match_result\": \"negative\", \"comment\": \"The patient does not meet any of the exclusion criteria as they are currently not enrolled in another therapeutic clinical study.\"}, {\"id\": 7, \"type\": \"exclusion\", \"criterion\": \"Any psychiatric or cognitive disorder that would limit the understanding or rendering of informed consent and/or compromise compliance with the requirements of this study; or known drug abuse/alcohol abuse;\", \"match_result\": \"negative\", \"comment\": \"The patient does not have any psychiatric or cognitive disorder that would limit the understanding or rendering of informed consent and/or compromise compliance with the requirements of this study. Additionally, there is no known drug abuse/alcohol abuse.\"}, {\"id\": 8, \"type\": \"exclusion\", \"criterion\": \"History of, or currently suspected, diffuse non-infectious pneumonitis or interstitial lung disease including:\", \"match_result\": \"negative\", \"comment\": \"Based on the patient's profile, there is no history of diffuse non-infectious pneumonitis or interstitial lung disease, nor any other conditions that would disqualify them from participating in the clinical trial.\"}, {\"id\": 9, \"type\": \"exclusion\", \"criterion\": \"Clinically important abnormalities in cardiac rhythm, conduction or morphology of resting ECG (e.g. complete left bundle branch block, second degree heart block, third degree heart block) OR:\", \"match_result\": \"negative\", \"comment\": \"The patient does not have any clinically important abnormalities in cardiac rhythm, conduction or morphology of resting ECG, nor do they have any other disqualifying factors as stated in the exclusion criterion.\"}, {\"id\": 10, \"type\": \"exclusion\", \"criterion\": \"Severely impaired (defined as Child-Pugh Class C) hepatic dysfunction;\", \"match_result\": \"negative\", \"comment\": \"The patient has EGFR activating mutation (exon 19 deletion), which is a specific target lesion, but they do not have severely impaired hepatic dysfunction (Child-Pugh Class C) as stated in the exclusion criterion. Their liver function tests such as ALT and AST are within normal limits, indicating no severe impairment.\"}, {\"id\": 11, \"type\": \"exclusion\", \"criterion\": \"Prior malignancy: Subjects will not be eligible if they have history of, or evidence of active disease of another concurrent malignancy within the previous five years. Exception would be effectively treated past history of non-melanoma skin cancer or in-situ cervical cancer with no evidence of active disease;\", \"match_result\": \"negative\", \"comment\": \"The patient has a history of adenocarcinoma in the lung, but it is EGFR activating mutation (exon 19 deletion) which is an exception to the exclusion criterion. Additionally, there is no evidence of active disease or concurrent malignancy within the previous five years.\"}, {\"id\": 12, \"type\": \"exclusion\", \"criterion\": \"Other severe acute or chronic medical condition that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study;\", \"match_result\": \"negative\", \"comment\": \"The patient's profile does not indicate any severe acute or chronic medical conditions that may increase the risk associated with study participation or study drug administration, nor do they have any factors that would interfere with the interpretation of study results. The patient has a specific type of lung cancer (Non-Small Cell Lung Cancer, Adenocarcinoma) and is eligible for the clinical trial based on other criteria.\"}, {\"id\": 13, \"type\": \"exclusion\", \"criterion\": \"Use of CYP2D6 substrates where minimal increases in concentration of the CYP2D6 substrate may lead to serious or life-threatening toxicities, including but not limited to procainamide, pimozide, and thioridazine from screening to randomization.\", \"match_result\": \"negative\", \"comment\": \"The patient does not use any CYP2D6 substrates, and their medical history and laboratory test results do not indicate any factors that would lead to serious or life-threatening toxicities.\"}, {\"id\": 0, \"type\": \"inclusion\", \"criterion\": \"Provision of a voluntarily given, personally signed and dated, written informed consent document;\", \"match_result\": \"positive\", \"comment\": \"The patient's profile matches the inclusion criterion as they have a diagnosis of Non-Small Cell Lung Cancer, Adenocarcinoma and an EGFR activating mutation (exon 19 deletion). Additionally, the patient does not have a history of small cell or carcinoid lung cancer nor EGFR exon 20 T790M or exon 20 insertion mutation. The patient also meets other criteria such as ECOG score of 0 and has at least one unirradiated target lesion according to RECIST v1.1.\"}, {\"id\": 1, \"type\": \"inclusion\", \"criterion\": \"Male or female adult as defined by local regulation;\"}, {\"id\": 2, \"type\": \"inclusion\", \"criterion\": \"The presence of an EGFR activating mutation (exon 19 deletion or the L858R mutation in exon 21) in tumor specimen determined by the local laboratory;\", \"match_result\": \"positive\", \"comment\": \"The patient has a confirmed EGFR activating mutation (exon 19 deletion) in their tumor specimen, which aligns with the inclusion criterion. Additionally, they have not received any systemic therapy for advanced NSCLC and meet the other specified criteria, further supporting the match result.\"}, {\"id\": 3, \"type\": \"inclusion\", \"criterion\": \"Evidence of newly diagnosed stage IIIB/IIIC/IV (based on Union for International Cancer Control (UICC) staging system version 8) or recurrent (minimum of 12 months disease free interval between completion of systemic therapy and recurrence of NSCLC required) NSCLC of adenocarcinoma histo- and/or cytopathology or its pathologically accepted variants using tumor specimen (assessed according to accepted standards by a local laboratory). For this purpose the World Health Organization/International Association of Study of Lung Cancer Histologic Classification of Lung Cancer Criteria will be used and the diagnosis of NSCLC NOS (not otherwise specified), squamous or mixed adeno-squamous lung carcinomas will not be allowed;\", \"match_result\": \"positive\", \"comment\": \"The patient has newly diagnosed stage IV NSCLC with adenocarcinoma, which meets the inclusion criterion. Additionally, the EGFR activating mutation (exon 19 deletion) supports the match.\"}, {\"id\": 4, \"type\": \"inclusion\", \"criterion\": \"Have an ECOG PS of 0 or 1;\", \"match_result\": \"positive\", \"comment\": \"The patient's EGFR activating mutation (exon 19 deletion) and ECOG score of 0 meet the inclusion criterion, which requires an ECOG PS of 0 or 1. The patient also has a history of NSCLC, which matches the criterion. Additionally, the patient does not have any history of small cell or carcinoid lung cancer, nor EGFR exon 20 T790M or exon 20 insertion mutation, which aligns with the criterion.\"}, {\"id\": 5, \"type\": \"inclusion\", \"criterion\": \"No prior treatment with systemic therapy for locally advanced or metastatic NSCLC. Completed neoadjuvant/adjuvant chemotherapy/immunotherapy and/or combined modality chemotherapy/radiation therapy permitted only in cases in which there is a minimum of 12 months disease free interval between completion of systemic therapy and recurrence of NSCLC. Prior treatment with a EGFR-TKI or other TKIs is not allowed;\", \"match_result\": \"negative\", \"comment\": \"The patient has a history of prior treatment with systemic therapy (EGFR-TKI) which is not allowed according to the inclusion criterion. This makes them ineligible for the clinical trial.\"}, {\"id\": 6, \"type\": \"inclusion\", \"criterion\": \"Radiologically measurable disease by RECIST v1.1 criteria:\", \"match_result\": \"positive\", \"comment\": \"The patient has radiologically measurable disease by RECIST v1.1 criteria as stated in the inclusion criterion, with an EGFR activating mutation (exon 19 deletion) and no history of small cell or carcinoid lung cancer, nor EGFR exon 20 T790M or exon 20 insertion mutation, which meets the condition specified.\"}, {\"id\": 7, \"type\": \"inclusion\", \"criterion\": \"At least one target lesion that has not previously been radiated, and is measurable according to RECIST v1.1;\", \"match_result\": \"positive\", \"comment\": \"The patient has Non-Small Cell Lung Cancer, Adenocarcinoma with a measurable target lesion according to RECIST v1.1 and no history of small cell or carcinoid lung cancer, nor EGFR exon 20 T790M or exon 20 insertion mutation. These conditions match the inclusion criterion.\"}, {\"id\": 8, \"type\": \"inclusion\", \"criterion\": \"Acceptable radiologic procedures for disease assessment include contrast enhanced conventional or spiral computed tomography (CT), or contrast enhanced magnetic resonance imaging (MRI); Non-contrast CT scan is acceptable only for subjects who are both allergic to intravenous contrast and unable to cooperate with MRI, or MRI is not available. The following are not allowed as sole documentation of target lesions: CT component of positron emission tomography (PET)/CT, ultrasound alone, nuclear scans (including bone or PET scans), chest X-ray or bone radiographs, and tumor markers;\", \"match_result\": \"positive\", \"comment\": \"The patient has Non-Small Cell Lung Cancer, Adenocarcinoma and an EGFR activating mutation (exon 19 deletion) which is a specific inclusion criteria. Additionally, the patient does not have any excluded features such as small cell or carcinoid lung cancer, nor EGFR exon 20 T790M or exon 20 insertion mutation. The RECIST v1.1 with at least one unirradiated target lesion also matches the criterion.\"}, {\"id\": 9, \"type\": \"inclusion\", \"criterion\": \"Adequate organ function, including:\"}, {\"id\": 10, \"type\": \"inclusion\", \"criterion\": \"Estimated creatinine clearance \\u226530 mL/min (as determined by Cockcroft-Gault formula or the study site's standard formula);\", \"match_result\": \"positive\", \"comment\": \"The patient has a creatinine clearance estimated at \\u226530 mL/min, which meets the criterion. Additionally, the patient's ECOG score is 0 and does not have any unirradiated target lesions that could affect their kidney function.\"}, {\"id\": 11, \"type\": \"inclusion\", \"criterion\": \"Absolute neutrophil count (ANC) \\u22651500 cells/mm3;\", \"match_result\": \"positive\", \"comment\": \"The patient's ANC (Absolute neutrophil count) is 16,000 cells/mm3, which meets the criteria of having an ANC \\u226515,000 cells/mm3. Additionally, the patient has a valid ECOG score of 0 and no history of small cell or carcinoid lung cancer.\"}, {\"id\": 12, \"type\": \"inclusion\", \"criterion\": \"Platelets \\u2265100,000 cells/mm3;\", \"match_result\": \"positive\", \"comment\": \"The patient's platelet count is 110,000 cells/mm, which meets the criterion requirement of \\u2265100,000 cells/mm.\"}, {\"id\": 13, \"type\": \"inclusion\", \"criterion\": \"Hemoglobin \\u226510.0 g/dL;\", \"match_result\": \"positive\", \"comment\": \"The patient's hemoglobin level is 11.0 g/dL, which meets the inclusion criterion's requirement of Hemoglobin \\u226510.0 g/dL.\"}, {\"id\": 14, \"type\": \"inclusion\", \"criterion\": \"Bilirubin \\u22641.5 x ULN;\", \"match_result\": \"positive\", \"comment\": \"The patient's profile aligns with the stated conditions or factors, specifically the bilirubin level is 1.2 x ULN, which is within the allowed range of \\u22641.5 x ULN.\"}, {\"id\": 15, \"type\": \"inclusion\", \"criterion\": \"AST (also known as SGOT) and ALT (also known as SGPT) \\u22642.5 x ULN (\\u22645.0 x ULN if hepatic metastases).\", \"match_result\": \"positive\", \"comment\": \"The patient's laboratory test results, including AST and ALT levels, are within normal limits, which aligns with the inclusion criterion.\"}, {\"id\": 16, \"type\": \"inclusion\", \"criterion\": \"Female subjects must be postmenopausal (defined as 12 months of amenorrhea following last menses), or they or their partners must be surgically sterile, or must agree to use effective contraception while receiving study treatment and for at least 3 months thereafter. The definition of effective contraception will be based on the judgment of the investigator using following criteria:\", \"match_result\": \"positive\", \"comment\": \"The patient's profile meets all the conditions stated in the inclusion criterion. The patient is postmenopausal and has no history of small cell or carcinoid lung cancer, nor EGFR exon 20 T790M or exon 20 insertion mutation. Additionally, the patient's biomarkers are within normal limits.\"}, {\"id\": 17, \"type\": \"inclusion\", \"criterion\": \"All female subjects with reproductive potential must have a negative pregnancy test (serum or urine) prior to starting study treatment;\", \"match_result\": \"positive\", \"comment\": \"The patient's profile shows a female subject with reproductive potential who has had a negative pregnancy test prior to starting study treatment. This meets the criterion as stated in the inclusion criteria.\"}, {\"id\": 18, \"type\": \"inclusion\", \"criterion\": \"Male subjects or their female partners must be surgically sterile or must agree to use effective contraception while receiving study treatment and for at least 3 months thereafter. The definition of effective contraception will be based on the judgment of the investigator. Or female partners must be postmenopausal (defined as 12 months of amenorrhea following last menses);\", \"match_result\": \"positive\", \"comment\": \"The patient's profile indicates that they have a male subject with an EGFR activating mutation (exon 19 deletion) and no history of small cell or carcinoid lung cancer. The patient also meets other criteria such as having at least one unirradiated target lesion, being RECIST v1.1 compliant, and not using any CYP2D6 substrates.\"}, {\"id\": 19, \"type\": \"inclusion\", \"criterion\": \"Willing and able to comply with study scheduled visits, treatment plans, laboratory tests, and other study procedures.\", \"match_result\": \"positive\", \"comment\": \"The patient's profile aligns with the stated conditions or factors in the inclusion criterion. The patient has Non-Small Cell Lung Cancer, Adenocarcinoma and an EGFR activating mutation (exon 19 deletion), which meets one of the criteria. Additionally, they have not received any systemic therapy for advanced NSCLC and meet other specific laboratory test requirements, further supporting their eligibility.\"}], \"embedding_score\": 5}, {\"trial_id\": \"NCT04989322\", \"gpt_result_score\": 3, \"criteria\": [{\"id\": 0, \"type\": \"exclusion\", \"criterion\": \"Prior exposure to immunotherapy or chemotherapy\", \"match_result\": \"negative\", \"comment\": \"The patient has not had prior exposure to immunotherapy or chemotherapy, which meets the criterion outlined in the clinical trial. Therefore, the patient does not meet the exclusion criterion.\"}, {\"id\": 1, \"type\": \"exclusion\", \"criterion\": \"Active untreated brain metastasis and/or carcinomatous meningitis\", \"match_result\": \"negative\", \"comment\": \"The patient has Non-Small Cell Lung Cancer with disease occurred in the lung, but there is no mention of active untreated brain metastasis and/or carcinomatous meningitis in the provided patient profile. Therefore, the criterion of 'Active untreated brain metastasis and/or carcinomatous meningitis' is not met.\"}, {\"id\": 2, \"type\": \"exclusion\", \"criterion\": \"Active, known or suspected autoimmune disease\", \"match_result\": \"neutral\", \"comment\": \"The patient profile does not provide sufficient information about the presence or absence of an active, known or suspected autoimmune disease. Further details or specific tests related to autoimmune diseases are needed to determine if the patient meets this criterion.\"}, {\"id\": 3, \"type\": \"exclusion\", \"criterion\": \"History of (noninfectious) pneumonitis that required systemic steroids or current pneumonitis/interstitial lung disease\", \"match_result\": \"negative\", \"comment\": \"The patient has a history of noninfectious pneumonitis that required systemic steroids, which does not meet the criteria. Therefore, the patient does not meet this criterion for the clinical trial.\"}, {\"id\": 4, \"type\": \"exclusion\", \"criterion\": \"Condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications\", \"match_result\": \"neutral\", \"comment\": \"The patient profile provides information on the disease, gene mutation, treatment history, biomarkers, and other health status. However, there is no explicit mention of the patient requiring systemic treatment with corticosteroids or other immunosuppressive medications as specified in the criterion. Further information is needed to determine if the patient meets this exclusion criterion.\"}, {\"id\": 5, \"type\": \"exclusion\", \"criterion\": \"Baseline proteinuria \\u2265 1 g/24 hrs\"}, {\"id\": 6, \"type\": \"exclusion\", \"criterion\": \"Electrolyte abnormalities that have not been corrected\", \"match_result\": \"negative\", \"comment\": \"The patient has a Platelets count of 110,000 cells/mm which is below the normal range (150,000 - 450,000 cells/mm), indicating an electrolyte abnormality. However, it is not specified in the patient profile that this abnormality has not been corrected. Therefore, while the patient has an electrolyte abnormality, it cannot be confirmed whether it has been corrected or not based on the provided information.\"}, {\"id\": 7, \"type\": \"exclusion\", \"criterion\": \"Significant cardiovascular impairment\", \"match_result\": \"neutral\", \"comment\": \"The patient profile does not provide specific information related to significant cardiovascular impairment. Further information regarding the patient's cardiovascular health status is needed to determine if this criterion is met.\"}, {\"id\": 8, \"type\": \"exclusion\", \"criterion\": \"Gastrointestinal pathology that might affect the absorption of lenvatinib\", \"match_result\": \"neutral\", \"comment\": \"More information is needed regarding the patient's gastrointestinal pathology that might affect the absorption of lenvatinib. The provided patient profile does not contain explicit information related to gastrointestinal pathology, so it is not possible to definitively determine if the patient meets this criterion.\"}, {\"id\": 9, \"type\": \"exclusion\", \"criterion\": \"Preexisting grade \\u2265 3 gastrointestinal or non gastrointestinal fistula\", \"match_result\": \"neutral\", \"comment\": \"The patient profile does not provide specific information regarding preexisting grade \\u2265 3 gastrointestinal or non-gastrointestinal fistula. Further information is needed to determine if the patient meets this criterion.\"}, {\"id\": 10, \"type\": \"exclusion\", \"criterion\": \"Bleeding or thrombotic disorders or subjects at risk for severe hemorrhage\", \"match_result\": \"negative\", \"comment\": \"The patient profile mentions 'Bleeding or thrombotic disorders' as an exclusion criterion for the clinical trial. Although the patient's platelet count is low (110,000 cells/mm), which could indicate a bleeding disorder, there is no explicit mention of a bleeding disorder or being at risk for severe hemorrhage in the provided information. Therefore, the patient does not meet this exclusion criterion.\"}, {\"id\": 11, \"type\": \"exclusion\", \"criterion\": \"Radiographic evidence of intratumoral caviations, encasement, or invasion of a major blood vessel\", \"match_result\": \"negative\", \"comment\": \"The patient profile mentions the disease occurred in the lung, but there is no specific mention of radiographic evidence of intratumoral caviations, encasement, or invasion of a major blood vessel. Therefore, the criterion is not met.\"}, {\"id\": 12, \"type\": \"exclusion\", \"criterion\": \"Known history of tuberculosis\", \"match_result\": \"negative\", \"comment\": \"The patient profile indicates no known history of tuberculosis, which aligns with the exclusion criterion in the clinical trial. Therefore, the patient meets the criterion of having no known history of tuberculosis.\"}, {\"id\": 13, \"type\": \"exclusion\", \"criterion\": \"Active, acute, or chronic clinically significant infections requiring therapy, including hepatitis B, hepatitis C, and HIV\", \"match_result\": \"neutral\", \"comment\": \"The patient profile does not provide specific information regarding active, acute, or chronic clinically significant infections requiring therapy, including hepatitis B, hepatitis C, and HIV. Further information is needed to determine if the patient meets this criterion.\"}, {\"id\": 14, \"type\": \"exclusion\", \"criterion\": \"ECG with long QTc interval \\u2265 470 ms\", \"match_result\": \"neutral\", \"comment\": \"The patient profile does not provide information regarding the ECG with long QTc interval, therefore more information is needed to determine if this criterion is met.\"}, {\"id\": 0, \"type\": \"inclusion\", \"criterion\": \"Histologically proven NSCLC\", \"match_result\": \"positive\", \"comment\": \"Patient has Non-Small Cell Lung Cancer, Adenocarcinoma, which fulfills the criterion of 'Histologically proven NSCLC'.\"}, {\"id\": 1, \"type\": \"inclusion\", \"criterion\": \"Unresectable or metastatic NSCLC, including squamous cell carcinoma, harboring sensitizing EGFR, ALK, or ROS1 genetic aberrations who have received standard of care targeted therapy and have progressed on treatment. Patients with known T790M mutation should have received osimertinib and failed.\", \"match_result\": \"neutral\", \"comment\": \"The patient's profile indicates Non-Small Cell Lung Cancer with adenocarcinoma, harboring an EGFR activating mutation (exon 19 deletion), which aligns with the genetic aberrations specified in the criteria. However, additional information is required to confirm if the patient has received standard of care targeted therapy, progressed on treatment, and if they have received osimertinib in case of T790M mutation. Furthermore, the patient's ECOG score, biomarkers, and treatment history do not provide conclusive evidence to determine if they meet the criteria.\"}, {\"id\": 2, \"type\": \"inclusion\", \"criterion\": \"Measurable disease per RECIST 1.1\", \"match_result\": \"positive\", \"comment\": \"The patient has Non-Small Cell Lung Cancer, Adenocarcinoma with measurable disease occurred in the lung, which aligns with the criterion of 'Measurable disease per RECIST 1.1'. Therefore, the patient meets this criterion.\"}, {\"id\": 3, \"type\": \"inclusion\", \"criterion\": \"ECOG performance status \\u2264 1\", \"match_result\": \"positive\", \"comment\": \"The patient's ECOG performance status is 0, which is less than or equal to 1 as required by the criterion. Therefore, the patient meets the ECOG performance status criterion for the clinical trial.\"}, {\"id\": 4, \"type\": \"inclusion\", \"criterion\": \"Adequate organ function\"}, {\"id\": 5, \"type\": \"inclusion\", \"criterion\": \"Adequately controlled blood pressure\", \"match_result\": \"neutral\", \"comment\": \"The patient profile provides some information about the disease, gene mutation, ECOG score, treatment history, biomarkers, and other health status. However, there is no specific mention of the patient's blood pressure status, which is required to determine if the criterion for 'Adequately controlled blood pressure' is met. More information about the patient's blood pressure is needed to make a definitive assessment.\"}], \"embedding_score\": 4}, {\"trial_id\": \"NCT05261399\", \"gpt_result_score\": 3, \"criteria\": [{\"id\": 0, \"type\": \"exclusion\", \"criterion\": \"Predominant squamous NSCLC, and small cell lung cancer. Prior or current treatment with a third-generation EGFR-TKI other than Osimertinib. Prior or current treatment with savolitinib or another MET inhibitors. Spinal cord compression or brain metastases, unless asymptomatic and are stable. History or active leptomeningeal carcinomatosis. Unresolved toxicities from any prior therapy greater than CTCAE Grade 1 with the exception of alopecia, haemoglobin \\u2265 9.0 g/dL, and Grade 2 prior platinum-therapy related neuropathy. Active/unstable cardiac diseases currently or within the last 6 months, clinically significant ECG abnormalities, and/or factors/medications that may affect QTc intervals. History of liver cirrhosis of any origin and clinical stage; or history of other serious liver disease or chronic disease with relevant liver involvement. Known serious active infection including, but not limited to, tuberculosis, or HIV, HBV or HCV or gastrointestinal disease. Receipt of live attenuated vaccine (including against COVID-19) within 30 days prior to the first dose of study intervention. Past medical history of ILD, drug-induced ILD, radiation pneumonitis, which required steroid treatment, or any evidence of clinically active ILD. Participants currently receiving medications or herbal supplements known to be strong inducers of cytochrome P450 (CYP)3A4 or strong inhibitors of CYP1A2.\", \"match_result\": \"neutral\", \"comment\": \"The patient's profile does not provide enough information to determine if they meet the exclusion criterion. Additional information is needed regarding the patient's history of specific treatments, cardiac diseases, liver cirrhosis, infections, ILD, and medications known to interact with CYP3A4 or CYP1A2.\"}, {\"id\": 0, \"type\": \"inclusion\", \"criterion\": \"Provision of signed and dated written ICF prior to any mandatory and non-mandatory study-specific procedures, sampling and analyses. Participant must be \\u226518 years (\\u2265 20 years of age in Japan) at the time of signing the informed consent. All genders are permitted.\"}, {\"id\": 1, \"type\": \"inclusion\", \"criterion\": \"Histologically or cytologically confirmed locally advanced or metastatic NSCLC which is not amenable to curative therapy. Must have at least one documented sensitising EGFR mutation: exon19 deletion, L858R mutation, and/or T790M. Documented radiologic progression on first- or second-line treatment with osimertinib as the most recent anti-cancer therapy. Mandatory provision of FFPE tumour tissue. MET overexpression and/or amplification in tumour specimen collected following progression on prior osimertinib treatment. Measurable disease as defined by RECIST 1.1. Adequate haematological, liver, renal and cardiac functions, and coagulation parameters. ECOG performance status of 0 or 1.\", \"match_result\": \"neutral\", \"comment\": \"The patient profile contains some information matching the criteria such as histologically confirmed NSCLC, ECOG performance status of 0, and an EGFR activating mutation (exon 19 deletion). However, additional information is needed to confirm if the patient meets all the criteria such as documented radiologic progression on osimertinib, mandatory provision of FFPE tumor tissue, MET overexpression/amplification, and adequate hematological, liver, renal, and cardiac functions.\"}, {\"id\": 2, \"type\": \"inclusion\", \"criterion\": \"Participant must be \\u226518 years (\\u2265 20 years of age in Japan) at the time of signing the informed consent. All genders are permitted.\"}, {\"id\": 3, \"type\": \"inclusion\", \"criterion\": \"Documented radiologic progression on first- or second-line treatment with osimertinib as the most recent anti-cancer therapy.\", \"match_result\": \"neutral\", \"comment\": \"The patient profile provides information on the disease type, gene mutation, ECOG score, treatment history, biomarkers, and other health status. However, there is no specific mention of documented radiologic progression on first- or second-line treatment with osimertinib as the most recent anti-cancer therapy. More information is needed to determine if the patient meets this criterion.\"}, {\"id\": 4, \"type\": \"inclusion\", \"criterion\": \"Mandatory provision of FFPE tumour tissue.\", \"match_result\": \"neutral\", \"comment\": \"The patient profile mentions the diagnosis of Non-Small Cell Lung Cancer, which aligns with the requirement for tumour tissue. However, the presence or availability of FFPE tumour tissue specifically is not explicitly stated in the patient profile. Further information is needed to determine if the patient meets this criterion.\"}, {\"id\": 5, \"type\": \"inclusion\", \"criterion\": \"MET overexpression and/or amplification in tumour specimen collected following progression on prior osimertinib treatment.\", \"match_result\": \"neutral\", \"comment\": \"More information is needed regarding the MET overexpression and/or amplification status in the tumour specimen collected following progression on prior osimertinib treatment to determine if the patient meets this criterion.\"}, {\"id\": 6, \"type\": \"inclusion\", \"criterion\": \"Measurable disease as defined by RECIST 1.1.\", \"match_result\": \"positive\", \"comment\": \"The patient has Non-Small Cell Lung Cancer with disease occurred in the lung, which fulfills the criterion of measurable disease as defined by RECIST 1.1.\"}, {\"id\": 7, \"type\": \"inclusion\", \"criterion\": \"Adequate haematological, liver, renal and cardiac functions, and coagulation parameters.\", \"match_result\": \"positive\", \"comment\": \"The patient meets the criterion of having adequate haematological, liver, renal, and cardiac functions, and coagulation parameters. Platelets, Creatinine, ALT (SGPT), AST (SGOT), Bilirubin, ANC, and Hemoglobin are within normal limits or close to the normal range. These values indicate that the patient's haematological, liver, renal, and cardiac functions, as well as coagulation parameters, are adequate for the clinical trial criteria.\"}, {\"id\": 8, \"type\": \"inclusion\", \"criterion\": \"ECOG performance status of 0 or 1.\", \"match_result\": \"positive\", \"comment\": \"The patient's ECOG performance status is 0, which meets the criterion of ECOG performance status of 0 or 1.\"}], \"embedding_score\": 3}, {\"trial_id\": \"NCT05526755\", \"gpt_result_score\": 2.4000000000000004, \"criteria\": [{\"id\": 0, \"type\": \"exclusion\", \"criterion\": \"Major surgery (including primary tumour surgery, excluding placement of vascular access) within 4 weeks prior to the first dose of study drug.\", \"match_result\": \"negative\", \"comment\": \"The patient has not undergone major surgery within 4 weeks prior to the first dose of study drug, which meets the criterion. Therefore, the patient does not meet the exclusion criterion for the clinical trial.\"}, {\"id\": 1, \"type\": \"exclusion\", \"criterion\": \"Participants currently receiving medications or herbal supplements known to be potent inducers of CYP3A4 (at least 3 weeks prior to first dose).\", \"match_result\": \"neutral\", \"comment\": \"The patient profile provides information on the disease, gene mutation, ECOG score, treatment history, biomarkers, and health status. However, there is no specific mention about the patient currently receiving medications or herbal supplements known to be potent inducers of CYP3A4. More information is needed to determine if the patient meets the exclusion criterion.\"}, {\"id\": 2, \"type\": \"exclusion\", \"criterion\": \"Participants who have had only segmentectomies or wedge resections.\", \"match_result\": \"neutral\", \"comment\": \"More information is needed regarding the type of surgery the patient has undergone (segmentectomy or wedge resection) to determine if they meet the criterion. Once this information is provided, the assessment can be updated accordingly.\"}, {\"id\": 3, \"type\": \"exclusion\", \"criterion\": \"History of other malignancies, except: adequately treated non-melanoma skin cancer, curatively treated in situ cancer, or other solid tumours curatively treated with no evidence of disease for > 5 years following the end of study intervention.\", \"match_result\": \"negative\", \"comment\": \"The patient has a history of malignancy (Non-Small Cell Lung Cancer, Adenocarcinoma), which is not allowed as per the clinical trial criterion. The patient's disease occurred in the lung, which is a solid tumor, and no evidence is provided to show that the patient has been disease-free for more than 5 years post-treatment.\"}, {\"id\": 4, \"type\": \"exclusion\", \"criterion\": \"Pre-operative or post-operative or planned radiation therapy for the current lung cancer.\", \"match_result\": \"negative\", \"comment\": \"The patient profile mentions 'No systemic therapy received for advanced NSCLC' which indicates that the patient has not undergone radiation therapy for the current lung cancer, thereby meeting the criterion. However, the criterion specifies exclusion of patients who have undergone pre-operative or post-operative or planned radiation therapy for the current lung cancer. Since the patient has not received systemic therapy, the specific type of treatment (radiation therapy) is not explicitly addressed in the profile, resulting in a negative match result for this criterion.\"}, {\"id\": 5, \"type\": \"exclusion\", \"criterion\": \"Pre-operative (neo-adjuvant) platinum-based or other chemotherapy.\", \"match_result\": \"neutral\", \"comment\": \"The patient profile provides detailed information about the non-small cell lung cancer, gene mutation, treatment history, biomarkers, and health status. However, there is no specific mention of pre-operative chemotherapy in the patient profile. More information about any previous chemotherapy treatment or current treatment plan is needed to determine if the patient meets the criterion.\"}, {\"id\": 6, \"type\": \"exclusion\", \"criterion\": \"Any prior anticancer or immunological therapy, including investigational therapy, for treatment of NSCLC other than standard platinum-based doublet post-operative adjuvant chemotherapy.\", \"match_result\": \"neutral\", \"comment\": \"The patient profile provides information about the EGFR activating mutation, ECOG score, treatment history, biomarkers, and other health status. However, there is no specific mention of prior anticancer or immunological therapy, including investigational therapy, for the treatment of NSCLC, which is the main criterion of exclusion in this case. More information is needed to determine if the patient meets this criterion.\"}, {\"id\": 7, \"type\": \"exclusion\", \"criterion\": \"Prior treatment with neoadjuvant or adjuvant EGFR tyrosine kinase inhibitor (TKI).\", \"match_result\": \"negative\", \"comment\": \"The patient has an EGFR activating mutation and has not received neoadjuvant or adjuvant EGFR tyrosine kinase inhibitor (TKI) treatment, which means the criterion of prior treatment with neoadjuvant or adjuvant EGFR TKI is not met.\"}, {\"id\": 8, \"type\": \"exclusion\", \"criterion\": \"Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of osimertinib.\", \"match_result\": \"positive\", \"comment\": \"The patient has Non-Small Cell Lung Cancer with an EGFR activating mutation, which aligns with the criteria for the clinical trial. The patient does not have refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of osimertinib.\"}, {\"id\": 9, \"type\": \"exclusion\", \"criterion\": \"Any of the following cardiac criteria: Mean resting corrected QT (QTc) interval > 470 msec, obtained from 3 electrocardiograms (ECGs). Any clinically important abnormalities in rhythm, conduction, or morphology of resting ECG. Any factors that increase the risk of QTc prolongation or risk of arrhythmic events. Heart failure, congenital long QT interval (QT) syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first-degree relatives or any concomitant medication known to prolong the QT interval and cause Torsades de Pointes (TdP).\", \"match_result\": \"neutral\", \"comment\": \"The patient profile does not provide specific information related to the cardiac criteria outlined in the clinical trial criterion. Further details regarding the patient's cardiac health, ECG results, and risk factors for QTc prolongation are needed to determine if the patient meets the exclusion criterion.\"}, {\"id\": 10, \"type\": \"exclusion\", \"criterion\": \"Past medical history of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis that required steroid treatment, or any evidence of clinically active ILD.\", \"match_result\": \"negative\", \"comment\": \"The patient profile does not have a past medical history of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis that required steroid treatment, or any evidence of clinically active ILD. Therefore, the patient does not meet the exclusion criterion for the clinical trial.\"}, {\"id\": 11, \"type\": \"exclusion\", \"criterion\": \"Inadequate bone marrow reserve or organ function.\", \"match_result\": \"negative\", \"comment\": \"The patient profile does show information about organ function, including platelets, creatinine, ALT, AST, and bilirubin levels. However, these values are within normal limits or slightly elevated, indicating adequate organ function. Therefore, the criterion of 'Inadequate bone marrow reserve or organ function' is not met in this case.\"}, {\"id\": 12, \"type\": \"exclusion\", \"criterion\": \"Women who are breastfeeding.\"}, {\"id\": 13, \"type\": \"exclusion\", \"criterion\": \"Heart failure, congenital long QT interval  QT  syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first-degree relatives or any concomitant medication known to prolong the QT interval and cause Torsades de Pointes  TdP .\", \"match_result\": \"positive\", \"comment\": \"The patient does not have any history of heart failure, congenital long QT interval syndrome, family history of long QT syndrome, unexplained sudden death under 40 years of age in first-degree relatives, or any concomitant medication known to prolong the QT interval and cause Torsades de Pointes (TdP). Therefore, the patient meets the criterion mentioned in the clinical trial.\"}, {\"id\": 14, \"type\": \"exclusion\", \"criterion\": \"Past medical history of interstitial lung disease  ILD , drug-induced ILD, radiation pneumonitis that required steroid treatment, or any evidence of clinically active ILD.\", \"match_result\": \"negative\", \"comment\": \"The patient has a past medical history of interstitial lung disease (ILD) which is an exclusion criterion for the clinical trial. According to the patient profile, there is evidence of clinically active ILD present, thus the patient does not meet the criteria.\"}, {\"id\": 15, \"type\": \"exclusion\", \"criterion\": \"Inadequate bone marrow reserve or organ function.\", \"match_result\": \"negative\", \"comment\": \"The patient profile indicates that the Platelets count is 110,000 cells/mm which is below the normal range (normal range: 150,000 to 450,000 platelets per microliter of blood). This indicates inadequate bone marrow reserve as per the criterion, resulting in not meeting the criteria for the clinical trial.\"}, {\"id\": 16, \"type\": \"exclusion\", \"criterion\": \"Women who are breastfeeding.\"}, {\"id\": 0, \"type\": \"inclusion\", \"criterion\": \"Male or female aged at least 18 years.\"}, {\"id\": 1, \"type\": \"inclusion\", \"criterion\": \"Histologically confirmed diagnosis of primary NSCLC on predominantly non-squamous histology.\", \"match_result\": \"positive\", \"comment\": \"The patient has non-squamous histology (adenocarcinoma), which meets the criterion of predominantly non-squamous histology for the diagnosis of primary NSCLC. Therefore, the patient profile matches the given criterion.\"}, {\"id\": 2, \"type\": \"inclusion\", \"criterion\": \"Magnetic Resonance Imaging (MRI) or contrast computed tomography (CT) scan of the brain.\", \"match_result\": \"neutral\", \"comment\": \"Based on the provided patient profile, there is no explicit mention of whether the patient has undergone Magnetic Resonance Imaging (MRI) or contrast computed tomography (CT) scan of the brain. Further information is needed to determine if this criterion is met.\"}, {\"id\": 3, \"type\": \"inclusion\", \"criterion\": \"Participants must be classified post-operatively as Stage II, IIIA, or IIIB on the basis of surgical pathologic criteria.\", \"match_result\": \"neutral\", \"comment\": \"More information about the post-operative classification of the patient based on surgical pathologic criteria is needed to determine if the patient meets the criterion. The provided patient profile does not include specific details regarding the post-operative classification as Stage II, IIIA, or IIIB.\"}, {\"id\": 4, \"type\": \"inclusion\", \"criterion\": \"Confirmation by the local laboratory that the tumour harbours one of the two common EGFR mutations (Ex19del, L858R), either alone or in combination with other EGFR mutations including de novo EGFR mutation resulting in substitution of threonine with methionine at amino acid position 790 in exon 20 of EGFR (T790M) or uncommon EGFR mutations G719X, S768I, and L861Q, either alone, in combination with each other, or in combination with other uncommon EGFR mutations (excluding all exon 20 insertions) (Uncommon EGFRm Cohort).\", \"match_result\": \"positive\", \"comment\": \"The patient has confirmed Non-Small Cell Lung Cancer with adenocarcinoma, which is in line with the trial criterion. The patient also has the EGFR activating mutation (exon 19 deletion) required by the trial criterion. Furthermore, the patient does not have a history of small cell or carcinoid lung cancer, EGFR exon 20 T790M mutation, or exon 20 insertion mutation, which aligns with the criteria. The patient's biomarkers such as Platelets, Creatinine, ALT, AST, Bilirubin, ECOG, ANC, and Hemoglobin are within acceptable limits as per the trial criterion. Therefore, the patient meets the criteria for the Uncommon EGFRm Cohort in the clinical trial.\"}, {\"id\": 5, \"type\": \"inclusion\", \"criterion\": \"Complete surgical resection of the primary NSCLC is mandatory. All gross disease must have been removed at the end of surgery. All surgical margins of resection must be negative for tumour.\", \"match_result\": \"negative\", \"comment\": \"The patient has Non-Small Cell Lung Cancer with adenocarcinoma in the lung, which matches the criterion. However, the patient has not undergone complete surgical resection of the primary NSCLC as required by the criterion. Therefore, the patient profile does not meet the criteria for this clinical trial.\"}, {\"id\": 6, \"type\": \"inclusion\", \"criterion\": \"Complete recovery from surgery and standard post-operative therapy (if applicable) at start of study intervention.\", \"match_result\": \"negative\", \"comment\": \"The patient has not undergone surgery according to the provided patient profile. Therefore, they do not meet the criterion of complete recovery from surgery at the start of the study intervention.\"}, {\"id\": 7, \"type\": \"inclusion\", \"criterion\": \"World Health Organisation Performance Status of 0 to 1.\", \"match_result\": \"positive\", \"comment\": \"The patient meets the criterion as the ECOG score is 0, which falls within the range of 0 to 1 specified in the World Health Organisation Performance Status criterion.\"}, {\"id\": 8, \"type\": \"inclusion\", \"criterion\": \"Female participants must be using highly effective contraceptive measures, and must have a negative pregnancy test prior to start of dosing if of childbearing potential.\", \"match_result\": \"neutral\", \"comment\": \"The patient profile provides information on the disease, gene mutation, ECOG score, received treatment, biomarkers, and other health status. However, there is no specific mention of the patient's contraceptive measures or pregnancy test status, which are the key criteria specified in the clinical trial. More information is needed to determine if the patient meets this criterion.\"}, {\"id\": 9, \"type\": \"inclusion\", \"criterion\": \"Male participants must use effective barrier contraception.\", \"match_result\": \"neutral\", \"comment\": \"The patient profile does not provide specific information about the use of effective barrier contraception by male participants. Further details are needed to determine if this criterion is met.\"}], \"embedding_score\": 2}, {\"trial_id\": \"NCT05133544\", \"gpt_result_score\": 0, \"criteria\": [{\"id\": 0, \"type\": \"exclusion\", \"criterion\": \"Patients will be excluded if they have history of inflammatory bowel disease, colorectal cancer, previous bowel resection, Peutz-Jeghers syndrome, familial adenomatous polyposis or other polyposis syndromes, bleeding tendency or severe comorbid illnesses for which polypectomy is considered unsafe.\", \"match_result\": \"neutral\", \"comment\": \"The patient profile provided does not contain sufficient information to determine if the patient meets the exclusion criterion. More information is needed regarding the patient's history of inflammatory bowel disease, colorectal cancer, previous bowel resection, Peutz-Jeghers syndrome, familial adenomatous polyposis, bleeding tendency, or severe comorbid illnesses for which polypectomy is considered unsafe.\"}, {\"id\": 1, \"type\": \"exclusion\", \"criterion\": \"Moreover, after randomization, if the cecum could not be intubated for various reasons or Boston Bowel Preparation Scale (BBPS) score is <2, these patients will be excluded\", \"match_result\": \"neutral\", \"comment\": \"The patient profile provides information on the disease, gene mutation, ECOG score, biomarkers, and other health status. However, specific details related to cecum intubation or BBPS score are not provided in the patient profile. More information is needed to determine if the patient meets the exclusion criterion.\"}, {\"id\": 0, \"type\": \"inclusion\", \"criterion\": \"All adult patients, aged 40 or above, undergoing outpatient colonoscopy in the Queen Mary Hospital, Tung Wah Hospital and Tuen Mun Hospital in Hong Kong will be recruited.\", \"match_result\": \"neutral\", \"comment\": \"The patient profile provided does not contain specific information about undergoing outpatient colonoscopy in the specified hospitals in Hong Kong. More information is needed to determine if the patient meets the criterion.\"}], \"embedding_score\": 1}], \"ranked_sql_trials\": [\"NCT04027647\", \"NCT04989322\", \"NCT05261399\", \"NCT05526755\", \"NCT05133544\", \"NCT05170204\", \"NCT04782557\", \"NCT05425940\", \"NCT05099172\", \"NCT05048797\"]}}]\n"
     ]
    }
   ],
   "source": [
    "print(final_output)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "clinmatch",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.5"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
